IE52535B1
(en)
*
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
US4637905A
(en)
*
|
1982-03-04 |
1987-01-20 |
Batelle Development Corporation |
Process of preparing microcapsules of lactides or lactide copolymers with glycolides and/or ε-caprolactones
|
FR2537980B1
(fr)
*
|
1982-12-17 |
1986-12-19 |
Sandoz Sa |
Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
|
US4652443A
(en)
*
|
1983-06-07 |
1987-03-24 |
Japan Atomic Energy Research Institute |
Slow-release composite and process for producing the same
|
CA1196864A
(fr)
*
|
1983-06-10 |
1985-11-19 |
Mattheus F.A. Goosen |
Composes d'insuline implantable et injectable a liberation regulee
|
CH656884A5
(de)
*
|
1983-08-26 |
1986-07-31 |
Sandoz Ag |
Polyolester, deren herstellung und verwendung.
|
CH661206A5
(fr)
*
|
1983-09-23 |
1987-07-15 |
Debiopharm Sa |
Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
|
JPS6097918A
(ja)
*
|
1983-11-01 |
1985-05-31 |
Sumitomo Chem Co Ltd |
インタ−フエロン持続性製剤
|
JPS60100516A
(ja)
*
|
1983-11-04 |
1985-06-04 |
Takeda Chem Ind Ltd |
徐放型マイクロカプセルの製造法
|
JPS60181029A
(ja)
*
|
1984-02-29 |
1985-09-14 |
Toyo Jozo Co Ltd |
徐放性製剤の製法
|
GB8416234D0
(en)
*
|
1984-06-26 |
1984-08-01 |
Ici Plc |
Biodegradable amphipathic copolymers
|
CA1236641A
(fr)
*
|
1984-07-06 |
1988-05-10 |
Motoaki Tanaka |
Copolymere d'acide lactique et d'acide glycolique et methode de production
|
US4666885A
(en)
*
|
1985-02-08 |
1987-05-19 |
Fernand Labrie |
Combination therapy for treatment of female breast cancer
|
US4760053A
(en)
*
|
1984-08-02 |
1988-07-26 |
Fernand Labrie |
Combination therapy for selected sex steroid dependent cancers
|
US4880635B1
(en)
*
|
1984-08-08 |
1996-07-02 |
Liposome Company |
Dehydrated liposomes
|
DE3434345A1
(de)
*
|
1984-09-19 |
1986-03-27 |
Hoechst Ag, 6230 Frankfurt |
Verwendung von (alpha)-interferonen zur bekaempfung von durchfaellen
|
DE3678308D1
(de)
*
|
1985-02-07 |
1991-05-02 |
Takeda Chemical Industries Ltd |
Verfahren zur herstellung von mikrokapseln.
|
FR2581544B1
(fr)
*
|
1985-05-10 |
1989-11-03 |
Univ Melbourne |
Procede pour provoquer une ovulation chez les juments et vehicule pharmaceutique associe
|
US5137874A
(en)
*
|
1985-07-29 |
1992-08-11 |
American Cyanamid Co. |
Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
|
US5169633A
(en)
*
|
1985-07-29 |
1992-12-08 |
American Cyanamid Company |
Continuous release phenylethanolamine derivative compositions
|
US5059422A
(en)
*
|
1985-07-29 |
1991-10-22 |
American Cyanamid Company |
Continuous release phenylethanolamine derivative compositions
|
US5102872A
(en)
*
|
1985-09-20 |
1992-04-07 |
Cetus Corporation |
Controlled-release formulations of interleukin-2
|
US4643191A
(en)
*
|
1985-11-29 |
1987-02-17 |
Ethicon, Inc. |
Crystalline copolymers of p-dioxanone and lactide and surgical devices made therefrom
|
JPH0725688B2
(ja)
*
|
1986-03-31 |
1995-03-22 |
住友製薬株式会社 |
Csf徐放性製剤
|
GB8609537D0
(en)
*
|
1986-04-18 |
1986-05-21 |
Ici Plc |
Polyesters
|
EP0248531A3
(fr)
*
|
1986-05-02 |
1988-09-28 |
Southern Research Institute |
Acides nucléiques encapsulés
|
CA1257199A
(fr)
*
|
1986-05-20 |
1989-07-11 |
Paul Y. Wang |
Preparation contenant une substance macromoleculaire ayant des proprietes biologiques liberee pendant plusieurs mois in vivo
|
US4962091A
(en)
*
|
1986-05-23 |
1990-10-09 |
Syntex (U.S.A.) Inc. |
Controlled release of macromolecular polypeptides
|
US6150328A
(en)
|
1986-07-01 |
2000-11-21 |
Genetics Institute, Inc. |
BMP products
|
JPH0725689B2
(ja)
*
|
1986-10-07 |
1995-03-22 |
中外製薬株式会社 |
顆粒球コロニ−刺激因子を含有する徐放性製剤
|
US5811128A
(en)
*
|
1986-10-24 |
1998-09-22 |
Southern Research Institute |
Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
|
US4981696A
(en)
*
|
1986-12-22 |
1991-01-01 |
E. I. Du Pont De Nemours And Company |
Polylactide compositions
|
DE3701625A1
(de)
*
|
1987-01-21 |
1988-08-04 |
Boehringer Ingelheim Kg |
Perorale arzneimittelzubereitung mit verzoegerter wirkstofffreigabe
|
DE3710175A1
(de)
*
|
1987-02-12 |
1988-08-25 |
Hoechst Ag |
Mehrteilige implantierbare arzneizubereitung mit langzeitwirkung
|
AU606383B2
(en)
*
|
1987-03-06 |
1991-02-07 |
Research Triangle Institute |
Polymer blends for selective biodegradability
|
US5028430A
(en)
*
|
1987-05-08 |
1991-07-02 |
Syntex (U.S.A.) Inc. |
Delivery systems for the controlled administration of LHRH analogs
|
US5000886A
(en)
*
|
1987-05-26 |
1991-03-19 |
American Cyanamid Company |
Silicone-hardened pharmaceutical microcapsules and process of making the same
|
DE3845000C2
(de)
*
|
1987-07-10 |
1998-11-19 |
Novartis Ag |
Anwendung von Octreotid zur Behandlung von Brustkrebs
|
GB8716324D0
(en)
*
|
1987-07-10 |
1987-08-19 |
Sandoz Ltd |
Organic compounds
|
US4866226A
(en)
*
|
1987-07-13 |
1989-09-12 |
Mitsubishi Denki Kabushiki Kaisha |
Multi-phase circuit breaker employing arc extinguishing apparatus
|
JPH0613602B2
(ja)
*
|
1987-07-14 |
1994-02-23 |
三井東圧化学株式会社 |
d▲l▼−乳酸−グリコール酸共重合物の製造方法
|
US4897268A
(en)
*
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
US5212154A
(en)
*
|
1987-08-14 |
1993-05-18 |
Akzo N.V. |
Preparation for treating complications in diabetes
|
NZ226171A
(en)
*
|
1987-09-18 |
1990-06-26 |
Ethicon Inc |
Gel formulation containing polypeptide growth factor
|
US5457093A
(en)
*
|
1987-09-18 |
1995-10-10 |
Ethicon, Inc. |
Gel formulations containing growth factors
|
GB2209937B
(en)
*
|
1987-09-21 |
1991-07-03 |
Depiopharm S A |
Water insoluble polypeptides
|
US5187150A
(en)
*
|
1987-10-14 |
1993-02-16 |
Debiopharm S.A. |
Polyester-based composition for the controlled release of polypeptide medicinal substances
|
JP2670680B2
(ja)
*
|
1988-02-24 |
1997-10-29 |
株式会社ビーエムジー |
生理活性物質含有ポリ乳酸系微小球およびその製造法
|
US4902515A
(en)
*
|
1988-04-28 |
1990-02-20 |
E. I. Dupont De Nemours And Company |
Polylactide compositions
|
FR2634770B1
(fr)
*
|
1988-07-29 |
1990-10-05 |
Rhone Poulenc Chimie |
Composition polyester erodable contenant de l'iode pour le traitement des eaux
|
US5502158A
(en)
*
|
1988-08-08 |
1996-03-26 |
Ecopol, Llc |
Degradable polymer composition
|
US5444113A
(en)
*
|
1988-08-08 |
1995-08-22 |
Ecopol, Llc |
End use applications of biodegradable polymers
|
US5424346A
(en)
*
|
1988-08-08 |
1995-06-13 |
Ecopol, Llc |
Biodegradable replacement of crystal polystyrene
|
US5252642A
(en)
*
|
1989-03-01 |
1993-10-12 |
Biopak Technology, Ltd. |
Degradable impact modified polyactic acid
|
US5180765A
(en)
*
|
1988-08-08 |
1993-01-19 |
Biopak Technology, Ltd. |
Biodegradable packaging thermoplastics from lactides
|
US5216050A
(en)
*
|
1988-08-08 |
1993-06-01 |
Biopak Technology, Ltd. |
Blends of polyactic acid
|
US6323307B1
(en)
|
1988-08-08 |
2001-11-27 |
Cargill Dow Polymers, Llc |
Degradation control of environmentally degradable disposable materials
|
US5250584A
(en)
*
|
1988-08-31 |
1993-10-05 |
G-C Dental Industrial Corp. |
Periodontium-regenerative materials
|
US5633002A
(en)
*
|
1988-10-04 |
1997-05-27 |
Boehringer Ingelheim Gmbh |
Implantable, biodegradable system for releasing active substance
|
US5247013A
(en)
*
|
1989-01-27 |
1993-09-21 |
Mitsui Toatsu Chemicals, Inc. |
Biocompatible polyester and production thereof
|
US4990336A
(en)
*
|
1989-02-08 |
1991-02-05 |
Biosearch, Inc. |
Sustained release dosage form
|
US5116964A
(en)
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
HU221589B
(hu)
*
|
1989-03-10 |
2002-11-28 |
Endorecherche Inc. |
Emlő- és méhrák kezelésére alkalmas kombinációs gyógyszerkészítmény és eljárás előállítására
|
NZ234227A
(en)
*
|
1989-06-30 |
1991-08-27 |
Smithkline Beecham Corp |
Delayed release dosage form
|
PH30995A
(en)
*
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
AU5856090A
(en)
*
|
1989-07-07 |
1991-02-06 |
Endorecherche Inc. |
Androgen derivatives for use in the inhibition of sex steroid activity
|
US5538739A
(en)
*
|
1989-07-07 |
1996-07-23 |
Sandoz Ltd. |
Sustained release formulations of water soluble peptides
|
HU221294B1
(en)
*
|
1989-07-07 |
2002-09-28 |
Novartis Ag |
Process for producing retarde compositions containing the active ingredient in a polymeric carrier
|
CA2062792C
(fr)
*
|
1989-07-07 |
2006-03-21 |
Fernard Labrie |
Traitement des maladies liees aux androgenes
|
US5225205A
(en)
*
|
1989-07-28 |
1993-07-06 |
Debiopharm S.A. |
Pharmaceutical composition in the form of microparticles
|
US5439688A
(en)
*
|
1989-07-28 |
1995-08-08 |
Debio Recherche Pharmaceutique S.A. |
Process for preparing a pharmaceutical composition
|
CH679207A5
(fr)
*
|
1989-07-28 |
1992-01-15 |
Debiopharm Sa |
|
EP0423484B1
(fr)
*
|
1989-10-16 |
1993-11-03 |
PCD-Polymere Gesellschaft m.b.H. |
Comprimé à libération retardée
|
US5126147A
(en)
*
|
1990-02-08 |
1992-06-30 |
Biosearch, Inc. |
Sustained release dosage form
|
US6517859B1
(en)
|
1990-05-16 |
2003-02-11 |
Southern Research Institute |
Microcapsules for administration of neuroactive agents
|
ATE226091T1
(de)
*
|
1990-05-16 |
2002-11-15 |
Southern Res Inst |
Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
|
CA2046830C
(fr)
|
1990-07-19 |
1999-12-14 |
Patrick P. Deluca |
Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
US5620959A
(en)
*
|
1990-07-31 |
1997-04-15 |
Glaxo Wellcome Inc. |
Bombesin antagonists
|
US6353030B1
(en)
|
1990-08-01 |
2002-03-05 |
Novartis Ag |
Relating to organic compounds
|
GB9016885D0
(en)
*
|
1990-08-01 |
1990-09-12 |
Scras |
Sustained release pharmaceutical compositions
|
NO302481B1
(no)
*
|
1990-10-16 |
1998-03-09 |
Takeda Chemical Industries Ltd |
Polymer for et preparat med forlenget frigjöring, samt preparat med forlenget frigjöring
|
US5342557A
(en)
*
|
1990-11-27 |
1994-08-30 |
United States Surgical Corporation |
Process for preparing polymer particles
|
US7285531B1
(en)
*
|
1991-04-10 |
2007-10-23 |
Acorda Therapeutics, Inc. |
Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
|
US5403595A
(en)
*
|
1991-05-07 |
1995-04-04 |
Dynagen, Inc. |
Controlled, sustained release delivery system for smoking cessation
|
US5486362A
(en)
*
|
1991-05-07 |
1996-01-23 |
Dynagen, Inc. |
Controlled, sustained release delivery system for treating drug dependency
|
HU222501B1
(hu)
*
|
1991-06-28 |
2003-07-28 |
Endorecherche Inc. |
MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
CH683149A5
(fr)
*
|
1991-07-22 |
1994-01-31 |
Debio Rech Pharma Sa |
Procédé pour la préparation de microsphères en matériau polymère biodégradable.
|
WO1993009229A1
(fr)
|
1991-11-04 |
1993-05-13 |
Genetics Institute, Inc. |
Proteines heterodimeres morphogenetiques d'os de recombinaison, compositions et procedes d'utilisation
|
US5876452A
(en)
*
|
1992-02-14 |
1999-03-02 |
Board Of Regents, University Of Texas System |
Biodegradable implant
|
US6013853A
(en)
*
|
1992-02-14 |
2000-01-11 |
The University Of Texas System |
Continuous release polymeric implant carrier
|
US5912015A
(en)
*
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
US5656297A
(en)
*
|
1992-03-12 |
1997-08-12 |
Alkermes Controlled Therapeutics, Incorporated |
Modulated release from biocompatible polymers
|
EP0630234B1
(fr)
*
|
1992-03-12 |
1997-06-11 |
Alkermes Controlled Therapeutics, Inc. |
Microspheres a liberation regulee contenant l'hormone adrenocorticotrope (acth)
|
US5429822A
(en)
*
|
1992-03-13 |
1995-07-04 |
Cambridge Scientific, Inc. |
Biodegradable bursting release system
|
US5780051A
(en)
*
|
1992-04-02 |
1998-07-14 |
Dynagen, Inc. |
Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
|
EP0641211A1
(fr)
*
|
1992-05-21 |
1995-03-08 |
Endorecherche Inc. |
INHIBITEURS D'ACTIVITE DE LA TESTOSTERONE 5$g(a)-REDUCTASE
|
GB9211268D0
(en)
*
|
1992-05-28 |
1992-07-15 |
Ici Plc |
Salts of basic peptides with carboxyterminated polyesters
|
US5674534A
(en)
*
|
1992-06-11 |
1997-10-07 |
Alkermes, Inc. |
Composition for sustained release of non-aggregated erythropoietin
|
US20030035845A1
(en)
*
|
1992-06-11 |
2003-02-20 |
Zale Stephen E. |
Composition for sustained release of non-aggregated erythropoietin
|
US5716644A
(en)
*
|
1992-06-11 |
1998-02-10 |
Alkermes, Inc. |
Composition for sustained release of non-aggregated erythropoietin
|
JP2651320B2
(ja)
*
|
1992-07-16 |
1997-09-10 |
田辺製薬株式会社 |
徐放性マイクロスフェア製剤の製造方法
|
FR2693905B1
(fr)
*
|
1992-07-27 |
1994-09-02 |
Rhone Merieux |
Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
|
US5922340A
(en)
|
1992-09-10 |
1999-07-13 |
Children's Medical Center Corporation |
High load formulations and methods for providing prolonged local anesthesia
|
US5281419A
(en)
*
|
1992-09-28 |
1994-01-25 |
Thomas Jefferson University |
Biodegradable drug delivery system for the prevention and treatment of osteomyelitis
|
ATE195652T1
(de)
*
|
1992-12-02 |
2000-09-15 |
Alkermes Inc |
Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung
|
TW333456B
(en)
*
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
UA61046C2
(en)
|
1992-12-07 |
2003-11-17 |
Takeda Chemical Industries Ltd |
Sustained-release preparation and method for its manufacture
|
US5863985A
(en)
*
|
1995-06-29 |
1999-01-26 |
Kinerton Limited |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US6221958B1
(en)
|
1993-01-06 |
2001-04-24 |
Societe De Conseils De Recherches Et D'applications Scientifiques, Sas |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US5672659A
(en)
*
|
1993-01-06 |
1997-09-30 |
Kinerton Limited |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
WO1994015587A2
(fr)
*
|
1993-01-06 |
1994-07-21 |
Kinerton Limited |
Conjugues moleculaires ioniques de polyesters biodegradables et de polypeptides biologiquement actifs
|
US5456917A
(en)
*
|
1993-04-12 |
1995-10-10 |
Cambridge Scientific, Inc. |
Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
|
GB9310030D0
(en)
*
|
1993-05-15 |
1993-06-30 |
Scras |
Dry processed particles and process for the preparation of the same
|
US5569467A
(en)
*
|
1993-05-15 |
1996-10-29 |
Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) |
Process for the preparation of microballs and microballs thus obtained
|
US5635216A
(en)
*
|
1993-12-16 |
1997-06-03 |
Eli Lilly And Company |
Microparticle compositions containing peptides, and methods for the preparation thereof
|
US6440457B1
(en)
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
DE69407292T2
(de)
*
|
1993-06-30 |
1998-06-25 |
Genentech Inc |
Verfahren zur herstellung von liposomen
|
JP3822232B2
(ja)
|
1993-08-30 |
2006-09-13 |
ベイラー・カレッジ・オブ・メディシン |
老化細胞由来dna合成阻害因子
|
US6291206B1
(en)
|
1993-09-17 |
2001-09-18 |
Genetics Institute, Inc. |
BMP receptor proteins
|
US5496923A
(en)
*
|
1993-09-20 |
1996-03-05 |
Mitsui Toatsu Chemicals, Inc. |
Purification process of aliphatic polyester
|
US6913767B1
(en)
|
1993-10-25 |
2005-07-05 |
Genentech, Inc. |
Compositions for microencapsulation of antigens for use as vaccines
|
US6080429A
(en)
*
|
1993-10-25 |
2000-06-27 |
Genentech, Inc. |
Method for drying microspheres
|
US5643605A
(en)
*
|
1993-10-25 |
1997-07-01 |
Genentech, Inc. |
Methods and compositions for microencapsulation of adjuvants
|
AU689184B2
(en)
|
1993-12-07 |
1998-03-26 |
Genetics Institute, Llc |
BMP-12, BMP-13 and tendon-inducing compositions thereof
|
US20020193338A1
(en)
*
|
1994-02-18 |
2002-12-19 |
Goldstein Steven A. |
In vivo gene transfer methods for wound healing
|
US5942496A
(en)
*
|
1994-02-18 |
1999-08-24 |
The Regent Of The University Of Michigan |
Methods and compositions for multiple gene transfer into bone cells
|
US5763416A
(en)
*
|
1994-02-18 |
1998-06-09 |
The Regent Of The University Of Michigan |
Gene transfer into bone cells and tissues
|
US5962427A
(en)
*
|
1994-02-18 |
1999-10-05 |
The Regent Of The University Of Michigan |
In vivo gene transfer methods for wound healing
|
US6074840A
(en)
*
|
1994-02-18 |
2000-06-13 |
The Regents Of The University Of Michigan |
Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
|
DE4406172C2
(de)
*
|
1994-02-25 |
2003-10-02 |
Sanol Arznei Schwarz Gmbh |
Polyester
|
US6551618B2
(en)
*
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
GB9412273D0
(en)
|
1994-06-18 |
1994-08-10 |
Univ Nottingham |
Administration means
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US5607686A
(en)
*
|
1994-11-22 |
1997-03-04 |
United States Surgical Corporation |
Polymeric composition
|
WO1996026716A1
(fr)
*
|
1995-02-28 |
1996-09-06 |
Innapharma, Inc. |
Formulations de microbille d'elcatonine a liberation lente pour le traitement de l'osteoporose
|
US5665702A
(en)
*
|
1995-06-06 |
1997-09-09 |
Biomeasure Incorporated |
Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
|
US6479457B2
(en)
|
1995-06-06 |
2002-11-12 |
Kinerton Limited |
Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
|
US5747058A
(en)
*
|
1995-06-07 |
1998-05-05 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system
|
US6413536B1
(en)
|
1995-06-07 |
2002-07-02 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system and medical or surgical device
|
US5968542A
(en)
*
|
1995-06-07 |
1999-10-19 |
Southern Biosystems, Inc. |
High viscosity liquid controlled delivery system as a device
|
US7833543B2
(en)
*
|
1995-06-07 |
2010-11-16 |
Durect Corporation |
High viscosity liquid controlled delivery system and medical or surgical device
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
US5942241A
(en)
*
|
1995-06-09 |
1999-08-24 |
Euro-Celtique, S.A. |
Formulations and methods for providing prolonged local anesthesia
|
US5955574A
(en)
|
1995-07-13 |
1999-09-21 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. |
Analogs of parathyroid hormone
|
US5925351A
(en)
|
1995-07-21 |
1999-07-20 |
Biogen, Inc. |
Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
EP0789045B1
(fr)
*
|
1995-08-29 |
2001-01-10 |
Kyowa Hakko Kogyo Co., Ltd. |
Processus de production d'acide polyhydroxy carboxylique
|
CA2230494A1
(fr)
*
|
1995-08-31 |
1997-03-06 |
Alkermes Controlled Therapeutics Inc. |
Composition se pretant a la liberation prolongee d'un agent
|
US5942253A
(en)
*
|
1995-10-12 |
1999-08-24 |
Immunex Corporation |
Prolonged release of GM-CSF
|
CA2192773C
(fr)
|
1995-12-15 |
2008-09-23 |
Hiroaki Okada |
Obtention d'une preparation a liberation prolongee pour injection
|
US5980945A
(en)
*
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
AU1732897A
(en)
*
|
1996-02-23 |
1997-09-10 |
Kyowa Hakko Kogyo Co. Ltd. |
Process for the preparation of polyhydroxycarboxylic acid
|
US5747060A
(en)
*
|
1996-03-26 |
1998-05-05 |
Euro-Celtique, S.A. |
Prolonged local anesthesia with colchicine
|
IE960308A1
(en)
*
|
1996-04-23 |
1997-11-05 |
Kinerton Ltd |
Sustained release ionic conjugate
|
RU2165942C2
(ru)
*
|
1996-04-23 |
2001-04-27 |
Кинертон Лимитид |
Биоразрушаемый сложный полиэфир и способ его получения (варианты)
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US5766877A
(en)
*
|
1996-05-10 |
1998-06-16 |
Amgen Inc. |
Genes encoding art, an agouti-related transcript
|
US5817343A
(en)
*
|
1996-05-14 |
1998-10-06 |
Alkermes, Inc. |
Method for fabricating polymer-based controlled-release devices
|
CA2260750C
(fr)
|
1996-06-24 |
2004-11-09 |
Euro-Celtique, S.A. |
Methodes sures d'anesthesie locale
|
US6046187A
(en)
*
|
1996-09-16 |
2000-04-04 |
Children's Medical Center Corporation |
Formulations and methods for providing prolonged local anesthesia
|
US5952455A
(en)
*
|
1996-10-11 |
1999-09-14 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing polyhydroxycarboxylic acid
|
BR9612752A
(pt)
|
1996-10-25 |
2000-01-18 |
Human Genome Sciences Inc |
Neutrocina
|
ES2221019T3
(es)
|
1996-10-31 |
2004-12-16 |
Takeda Chemical Industries, Ltd. |
Preparacion de liberacion mantenida.
|
US6156728A
(en)
|
1996-11-01 |
2000-12-05 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6593290B1
(en)
|
1996-11-01 |
2003-07-15 |
Genentech, Inc. |
Treatment of inner ear hair cells
|
US6919373B1
(en)
|
1996-11-12 |
2005-07-19 |
Alza Corporation |
Methods and devices for providing prolonged drug therapy
|
US5919656A
(en)
*
|
1996-11-15 |
1999-07-06 |
Amgen Canada Inc. |
Genes encoding telomerase protein 1
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
US20020111603A1
(en)
|
1996-12-02 |
2002-08-15 |
Societe De Conseils De Recherches Et D'application |
Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process
|
US7138511B1
(en)
|
1997-01-28 |
2006-11-21 |
The Regents Of The University Of California |
Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6171788B1
(en)
|
1997-01-28 |
2001-01-09 |
The Regents Of The University Of California |
Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US6475724B1
(en)
|
1997-01-28 |
2002-11-05 |
The Regents Of The University Of California |
Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
|
US7235524B2
(en)
*
|
1997-01-31 |
2007-06-26 |
Applied Research System Ars Holding N.V. |
Medicaments for initiating ovulation
|
US5945126A
(en)
*
|
1997-02-13 |
1999-08-31 |
Oakwood Laboratories L.L.C. |
Continuous microsphere process
|
US6071982A
(en)
*
|
1997-04-18 |
2000-06-06 |
Cambridge Scientific, Inc. |
Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
|
US20060025328A1
(en)
*
|
1997-05-28 |
2006-02-02 |
Burns Patrick J |
Compositions suitable for controlled release of the hormone GnRH and its analogs
|
CA2291221A1
(fr)
|
1997-05-30 |
1998-12-03 |
Human Genome Sciences, Inc. |
32 proteines secretees par l'homme
|
US6867181B1
(en)
|
1997-06-02 |
2005-03-15 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
|
US6663899B2
(en)
|
1997-06-13 |
2003-12-16 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
US6113947A
(en)
*
|
1997-06-13 |
2000-09-05 |
Genentech, Inc. |
Controlled release microencapsulated NGF formulation
|
EP1009390A4
(fr)
|
1997-07-02 |
2004-05-06 |
Euro Celtique Sa |
Anesthesie a effet prolonge injectee dans les interlignes articulaires et corporelles
|
US6994851B1
(en)
|
1997-07-10 |
2006-02-07 |
Mannkind Corporation |
Method of inducing a CTL response
|
US6977074B2
(en)
*
|
1997-07-10 |
2005-12-20 |
Mannkind Corporation |
Method of inducing a CTL response
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
DE69840361D1
(de)
|
1997-07-30 |
2009-01-29 |
Univ Emory |
Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
WO1999014240A1
(fr)
|
1997-09-17 |
1999-03-25 |
Human Genome Sciences, Inc. |
Proteine de type recepteur d'interleukine 17
|
WO1999024061A1
(fr)
|
1997-11-07 |
1999-05-20 |
Chiron Corporation |
Procede de production de formulations d'igf-1 a liberation echelonnee
|
US6372880B1
(en)
|
1997-12-25 |
2002-04-16 |
Mitsui Chemicals, Inc. |
Copolymer and process for preparing the same
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
RU2237471C2
(ru)
*
|
1998-01-29 |
2004-10-10 |
Поли-Мед Инк. |
Абсорбируемые микрочастицы
|
DK1051194T3
(da)
|
1998-01-29 |
2003-09-01 |
Kinerton Ltd |
Fremgangsmåde til fremstilling af absorberbare mikropartikler
|
EP2050762A3
(fr)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Nouvelles polypeptides et acides nucléiques les codant
|
US20030180368A1
(en)
*
|
1998-03-14 |
2003-09-25 |
Cenes Drug Delivery Limited |
Production of microparticles
|
JP4532733B2
(ja)
|
1998-03-17 |
2010-08-25 |
ジェネンテック, インコーポレイテッド |
Vegfおよびbmp1と相同なポリペプチド群
|
EP1093457B8
(fr)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Analogue de chaine gamma commune de recepteur de cytokine
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
US7662409B2
(en)
*
|
1998-09-25 |
2010-02-16 |
Gel-Del Technologies, Inc. |
Protein matrix materials, devices and methods of making and using thereof
|
US20030007991A1
(en)
*
|
1998-09-25 |
2003-01-09 |
Masters David B. |
Devices including protein matrix materials and methods of making and using thereof
|
BR9915025A
(pt)
|
1998-10-09 |
2001-08-14 |
Biogen Inc |
Reversão de choque sistêmico induzido por vìrus e insuficiência respiratória por bloqueio da via linfotoxina-beta
|
US6143314A
(en)
*
|
1998-10-28 |
2000-11-07 |
Atrix Laboratories, Inc. |
Controlled release liquid delivery compositions with low initial drug burst
|
US6565874B1
(en)
*
|
1998-10-28 |
2003-05-20 |
Atrix Laboratories |
Polymeric delivery formulations of leuprolide with improved efficacy
|
US6270802B1
(en)
|
1998-10-28 |
2001-08-07 |
Oakwood Laboratories L.L.C. |
Method and apparatus for formulating microspheres and microcapsules
|
ATE357260T1
(de)
*
|
1998-11-02 |
2007-04-15 |
Sod Conseils Rech Applic |
Lactongruppen tragende absorbierbare polymere
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
US6365173B1
(en)
|
1999-01-14 |
2002-04-02 |
Efrat Biopolymers Ltd. |
Stereocomplex polymeric carriers for drug delivery
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US6727224B1
(en)
|
1999-02-01 |
2004-04-27 |
Genetics Institute, Llc. |
Methods and compositions for healing and repair of articular cartilage
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
NZ551331A
(en)
|
1999-02-03 |
2008-08-29 |
Amgen Inc |
Methods using polypeptides involved in immune response
|
US7708993B2
(en)
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
WO2000050620A2
(fr)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Endokine alpha humain et methodes d'utilisation
|
AU2875700A
(en)
|
1999-02-26 |
2000-09-14 |
Chiron Corporation |
Microemulsions with adsorbed macromoelecules and microparticles
|
WO2000054797A2
(fr)
|
1999-03-17 |
2000-09-21 |
Novartis Ag |
Compositions pharmaceutiques
|
WO2000058479A1
(fr)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Genes et polypeptides beta secretase
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
US20030166561A1
(en)
*
|
1999-06-18 |
2003-09-04 |
Cooper Garth J. S. |
Peptide
|
MXPA01013236A
(es)
|
1999-06-28 |
2002-06-21 |
Genentech Inc |
Metodos para hacer ligando apo-2 mediante el uso de iones metalicos divalentes.
|
US7713739B1
(en)
|
2000-11-17 |
2010-05-11 |
Novartis Vaccines And Diagnostics, Inc. |
Microparticle-based transfection and activation of dendritic cells
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
ES2225241T3
(es)
|
1999-10-15 |
2005-03-16 |
Genetics Institute, Llc |
Formulaciones de acido hialuronico para suministrar proteinas osteogenicas.
|
US7078382B1
(en)
|
1999-11-02 |
2006-07-18 |
Genentech, Inc. |
Modulation of eNOS activity and therapeutic uses thereof
|
US6682754B2
(en)
*
|
1999-11-24 |
2004-01-27 |
Willmar Poultry Company, Inc. |
Ovo delivery of an immunogen containing implant
|
US6465425B1
(en)
|
2000-02-10 |
2002-10-15 |
Alkermes Controlled Therapeutics, Inc. |
Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
|
US20030103978A1
(en)
|
2000-02-23 |
2003-06-05 |
Amgen Inc. |
Selective binding agents of osteoprotegerin binding protein
|
EP1265630B1
(fr)
*
|
2000-03-24 |
2006-06-07 |
Genentech, Inc. |
Utilisation de l'insuline pour traiter des affections des cartilages
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
AU2001266557A1
(en)
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU6342101A
(en)
*
|
2000-05-24 |
2001-12-03 |
Jordan Loyal Holtzman |
Agents and methods for increasing brain chaperonin levels
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
US20040170665A1
(en)
*
|
2000-06-02 |
2004-09-02 |
Allergan, Inc. |
Intravitreal botulinum toxin implant
|
AU2001282856A1
(en)
|
2000-06-15 |
2001-12-24 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP2792747A1
(fr)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse
|
CA2648051A1
(fr)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions et procedes de diagnostic et de traitement de troubles dont l'angiogenese
|
JP2004519205A
(ja)
|
2000-06-28 |
2004-07-02 |
アムジェン インコーポレイテッド |
胸腺間質リンホポイエチンレセプター分子およびその使用
|
WO2002012369A1
(fr)
†
|
2000-08-07 |
2002-02-14 |
Wako Pure Chemical Industries, Ltd. |
Polymere d'acide lactique et son procede de preparation
|
US6362308B1
(en)
|
2000-08-10 |
2002-03-26 |
Alkermes Controlled Therapeutics Inc. Ii |
Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
|
US6565888B1
(en)
|
2000-08-23 |
2003-05-20 |
Alkermes Controlled Therapeutics, Inc. |
Methods and compositions for the targeted delivery of biologically active agents
|
EP1317283B1
(fr)
|
2000-09-14 |
2011-07-06 |
Biogen Idec MA Inc. |
Agonistes du recepteur tweak utiles comme agents antiangiogeniques
|
AU2001296770A1
(en)
*
|
2000-10-06 |
2002-04-15 |
Durect Corporation |
Devices and methods for management of inflammation
|
DE10055742B4
(de)
|
2000-11-10 |
2006-05-11 |
Schwarz Pharma Ag |
Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
|
US8470359B2
(en)
|
2000-11-13 |
2013-06-25 |
Qlt Usa, Inc. |
Sustained release polymer
|
US7776310B2
(en)
|
2000-11-16 |
2010-08-17 |
Microspherix Llc |
Flexible and/or elastic brachytherapy seed or strand
|
EP1337634A2
(fr)
|
2000-11-28 |
2003-08-27 |
Amgen Inc. |
Nouveaux polypeptides impliques dans la reponse immunitaire
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
AU2001298061A1
(en)
|
2000-12-13 |
2003-07-09 |
Purdue Research Foundation |
Microencapsulation of drugs by solvent exchange
|
US20030152637A1
(en)
*
|
2001-01-25 |
2003-08-14 |
Mark Chasin |
Local anesthetic, and method of use
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
GB0111628D0
(en)
|
2001-05-11 |
2001-07-04 |
Scancell Ltd |
Binding member
|
JP2005500280A
(ja)
|
2001-06-01 |
2005-01-06 |
ワイエス |
骨形成タンパク質(bmp)をコードする配列の全身投与のための組成物および方法
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
TWI267378B
(en)
|
2001-06-08 |
2006-12-01 |
Wyeth Corp |
Calcium phosphate delivery vehicles for osteoinductive proteins
|
EP1408876A4
(fr)
|
2001-06-22 |
2004-09-22 |
Durect Corp |
Implants coaxiaux a liberation prolongee d'ordre 0
|
PT2087908T
(pt)
|
2001-06-26 |
2018-07-16 |
Amgen Inc |
Anticorpos contra opgl
|
AR034641A1
(es)
|
2001-06-29 |
2004-03-03 |
Takeda Pharmaceutical |
Composicion de liberacion controlada y metodo para producirla
|
AU2002335657A1
(en)
|
2001-08-24 |
2003-03-10 |
Neuronz Biosciences, Inc. |
Neural regeneration peptide and methods for their use in treatment of brain damage
|
KR101008785B1
(ko)
|
2001-08-29 |
2011-01-14 |
제넨테크, 인크. |
유사분열촉진 활성을 가진 Bv8 핵산 및 폴리펩티드
|
JP3993560B2
(ja)
*
|
2001-08-30 |
2007-10-17 |
ステム セル セラピューティクス インコーポレイテッド |
神経幹細胞の分化およびその治療用途
|
GB0122113D0
(en)
*
|
2001-09-11 |
2001-10-31 |
Astrazeneca Ab |
Composition
|
AU2002325711C1
(en)
*
|
2001-09-14 |
2008-05-29 |
Stem Cell Therapeutics Inc. |
Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
|
EP1430113A2
(fr)
*
|
2001-09-18 |
2004-06-23 |
Stem Cell Therapeutics Inc. |
Effet de l'hormone de croissance et de l'igf-1 sur les cellules souches neuronales et leur application en therapeutique
|
MXPA04002751A
(es)
|
2001-09-24 |
2005-09-08 |
Univ Oregon Health & Science |
Modificacion del comportamiento de alimentacion.
|
EP2348043A1
(fr)
|
2001-10-02 |
2011-07-27 |
Genentech, Inc. |
Variantes du ligand APO-2 et leurs utilisations
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
US20030077282A1
(en)
|
2001-10-12 |
2003-04-24 |
Bigler Michael Eric |
Use of bispecific antibodies to regulate immune responses
|
ES2351786T3
(es)
|
2001-11-13 |
2011-02-10 |
Genentech, Inc. |
Formulaciones con ligando apo2/trail y usos de las mismas.
|
ES2329346T3
(es)
*
|
2001-11-14 |
2009-11-25 |
Durect Corporation |
Composicion de deposito inyectable.
|
HK1077740A1
(en)
|
2001-12-20 |
2006-02-24 |
Ct Ingenieria Genetica Biotech |
Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
|
EP2261250B1
(fr)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
Protéines de fusion d'albumine et GCSF
|
AU2003201998C1
(en)
|
2002-01-10 |
2012-10-25 |
Imperial Innovations Limited |
Modification of feeding behavior
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
AU2003225895A1
(en)
*
|
2002-03-19 |
2003-10-08 |
Purdue Research Foundation |
Microencapsulation using ultrasonic atomizers
|
AU2003243139B2
(en)
|
2002-04-05 |
2007-06-21 |
Amgen Inc. |
Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
|
WO2003087163A1
(fr)
|
2002-04-15 |
2003-10-23 |
Chugai Seiyaku Kabushiki Kaisha |
Procede d'elaboration d'une banque scdb
|
DE60327199D1
(de)
|
2002-04-26 |
2009-05-28 |
Chugai Pharmaceutical Co Ltd |
Verfahren zum screening auf agonistische antikörper
|
US8623393B2
(en)
|
2002-04-29 |
2014-01-07 |
Gel-Del Technologies, Inc. |
Biomatrix structural containment and fixation systems and methods of use thereof
|
WO2003099320A1
(fr)
|
2002-05-24 |
2003-12-04 |
Zensun (Shanghai) Sci-Tech.Ltd |
Procedes et compositions a base de neureguline pour le traitement de la myocardite virale et de la myocardiopathie dilatee
|
EP2305710A3
(fr)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Bibliothèques de phages et anticorps synthétiques
|
DE10227232A1
(de)
*
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
US20060141561A1
(en)
|
2002-06-24 |
2006-06-29 |
Kelley Robert F |
Apo-2 ligand/trail variants and uses thereof
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
US20050232995A1
(en)
|
2002-07-29 |
2005-10-20 |
Yam Nyomi V |
Methods and dosage forms for controlled delivery of paliperidone and risperidone
|
CA2492442A1
(fr)
*
|
2002-07-31 |
2004-02-05 |
Stem Cell Therapeutics Inc. |
Procede d'amelioration de la proliferation, de la differentiation et de la survie de cellules souches neurales au moyen du polypeptide d'activation d'adenylate cyclase hypophysaire (pacap)
|
US20040142393A1
(en)
*
|
2002-08-01 |
2004-07-22 |
Cooper Garth James Smith |
Methods of use of compounds with preptin function
|
US8075585B2
(en)
*
|
2002-08-29 |
2011-12-13 |
Stryker Corporation |
Device and method for treatment of a vascular defect
|
NZ605429A
(en)
|
2002-09-06 |
2014-08-29 |
Amgen Inc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
WO2004034988A2
(fr)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Anticorps humains neutralisants anti-ifn-$g(g) utilises comme inhibiteurs selectifs des voies de ifn-$g(g)
|
US20040086532A1
(en)
*
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
MXPA05005192A
(es)
|
2002-11-15 |
2005-09-08 |
Idenix Cayman Ltd |
Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
|
ES2347239T3
(es)
|
2002-12-02 |
2010-10-27 |
Amgen Fremont Inc. |
Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
|
EP2218448B1
(fr)
|
2002-12-13 |
2015-09-23 |
Durect Corporation |
Forme d'administration orale de medicaments comprenant un vehicule liquide de haute viscosite
|
US7022481B2
(en)
|
2002-12-19 |
2006-04-04 |
Rosetta Inpharmatics Llc |
Methods of using glucan synthase pathway reporter genes to screen for antifungal compounds
|
JP2006517191A
(ja)
|
2002-12-30 |
2006-07-20 |
アムジエン・インコーポレーテツド |
共刺激因子を用いた併用療法
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
EP1440992A1
(fr)
*
|
2003-01-21 |
2004-07-28 |
Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) |
Système catalytique de (co)polymérisation du lactide et du glycolide
|
SI1594517T1
(sl)
|
2003-01-28 |
2007-10-31 |
Microbia Inc |
Sestavki za zdravljenje gastrointestinalnih motenj
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
GB0304726D0
(en)
*
|
2003-03-01 |
2003-04-02 |
Ardana Bioscience Ltd |
New Process
|
EP1601332A4
(fr)
|
2003-03-07 |
2012-05-02 |
Verenium Corp |
Hydrolases, acides nucleiques les codant, et procedes de fabrication et d'utilisation correspondants
|
NZ541480A
(en)
|
2003-03-12 |
2008-03-28 |
Genentech Inc |
Use of Bv8 and/or EG-VEGF to promote hematopoiesis
|
EP1622691B1
(fr)
*
|
2003-03-14 |
2011-05-25 |
The Trustees of Columbia University in the City of New York |
Systemes et procedes de traitements sanguins possedant un dispositif d'echange microfluidique sans membrane
|
US20060076295A1
(en)
*
|
2004-03-15 |
2006-04-13 |
The Trustees Of Columbia University In The City Of New York |
Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
|
RS54160B1
(sr)
|
2003-03-19 |
2015-12-31 |
Biogen Idec Ma Inc. |
Protein koji se vezuje za nogo receptor
|
EP1613750B1
(fr)
|
2003-03-19 |
2015-10-14 |
Amgen Fremont Inc. |
Anticorps contre l'antigene de lymphocytes t, du domaine d'immunoglobuline et du domaine 1 de mucine (tim-1) et leurs utilisations
|
WO2004103390A2
(fr)
|
2003-05-15 |
2004-12-02 |
Trustees Of Tufts College |
Agents therapeutiques comprenant des analogues stables de peptides et de polypeptides
|
WO2004103313A2
(fr)
|
2003-05-20 |
2004-12-02 |
The American National Red Cross |
Methodes de reduction de la permeabilite vasculaire d'un tissu par inhibition de l'activateur tissulaire du plasminogene (tpa) et inhibiteurs tpa utilises dans ces methodes
|
CN104059147A
(zh)
|
2003-06-27 |
2014-09-24 |
艾默根佛蒙特有限公司 |
针对表皮生长因子受体的缺失突变体的抗体及其使用
|
DK1660039T3
(en)
|
2003-07-18 |
2017-01-16 |
Oakwood Laboratories L L C |
PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
|
RS53476B
(en)
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Hepatocyte Growth Factor Binders
|
US8541051B2
(en)
*
|
2003-08-14 |
2013-09-24 |
Halliburton Energy Services, Inc. |
On-the fly coating of acid-releasing degradable material onto a particulate
|
WO2005020933A2
(fr)
*
|
2003-09-02 |
2005-03-10 |
University Of South Florida |
Nanoparticules pour apport de medicament
|
GB0320806D0
(en)
|
2003-09-05 |
2003-10-08 |
Astrazeneca Ab |
Therapeutic treatment
|
EP1667521B1
(fr)
|
2003-09-12 |
2011-12-07 |
Tercica, Inc. |
Methodes de traitement de la deficience du facteur de croissance de type insuline 1 (igf-1)
|
SI1675608T1
(sl)
|
2003-09-12 |
2007-08-31 |
Wyeth Corp |
Injektibilne trdne paličice kalcijevega fosfata za dajanje osteogenih proteinov
|
US7783006B2
(en)
*
|
2003-10-10 |
2010-08-24 |
Xoft, Inc. |
Radiation treatment using x-ray source
|
US7309232B2
(en)
*
|
2003-10-10 |
2007-12-18 |
Dentigenix Inc. |
Methods for treating dental conditions using tissue scaffolds
|
WO2005035753A1
(fr)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps a double specificite remplaçant une proteine fonctionnelle
|
US20050080313A1
(en)
*
|
2003-10-10 |
2005-04-14 |
Stewart Daren L. |
Applicator for radiation treatment of a cavity
|
AU2003271186A1
(en)
|
2003-10-14 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
EP1684791A4
(fr)
|
2003-10-27 |
2009-07-01 |
Amgen Inc |
Compositions et procedes de modulation de la reaction immunitaire a un agent therapeutique immunogene
|
EP1682537B1
(fr)
|
2003-11-05 |
2012-03-28 |
SARcode Bioscience Inc. |
Modulateurs de l'adhesion cellulaire
|
CN100534527C
(zh)
*
|
2003-12-30 |
2009-09-02 |
杜雷科特公司 |
用于控制释放优选为GnRH的活性剂的优选含有PEG和PLG的混合物的聚合植入物
|
AU2004313245B2
(en)
*
|
2003-12-30 |
2011-04-14 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
|
JP2007517522A
(ja)
*
|
2004-01-07 |
2007-07-05 |
トリメリス,インコーポレーテッド |
HIVgp41HR2由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
|
WO2005074650A2
(fr)
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Polypeptides a faisceau a quatre helices (4hb) humains modifies, et leur utilisation
|
US20070066525A1
(en)
*
|
2004-02-04 |
2007-03-22 |
Lee John C |
Compositions and therapeutic methods using morphogenic proteins
|
US7846898B2
(en)
|
2004-02-13 |
2010-12-07 |
Stem Cell Therapeutics Corp. |
Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
|
WO2005090564A1
(fr)
|
2004-03-19 |
2005-09-29 |
Genomidea Inc. |
Gene activant le developpement de cellules endotheliales vasculaires
|
US20050260679A1
(en)
|
2004-03-19 |
2005-11-24 |
Sirid-Aimee Kellerman |
Reducing the risk of human anti-human antibodies through V gene manipulation
|
AU2005227322A1
(en)
|
2004-03-23 |
2005-10-06 |
Biogen Idec Ma Inc. |
Receptor coupling agents and therapeutic uses thereof
|
GB0410627D0
(en)
|
2004-05-12 |
2004-06-16 |
Scancell Ltd |
Specific binding members
|
EP1598428A1
(fr)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Procédés et trousses pour la détection d'angioedema héréditaire type III
|
CN106434833A
(zh)
|
2004-05-23 |
2017-02-22 |
杰勒德·M·豪斯 |
Theramutein调节剂
|
JP5201987B2
(ja)
|
2004-05-25 |
2013-06-05 |
ストライカー コーポレイション |
軟骨欠損を処置するための、形態形成タンパク質の使用
|
AU2005265163B2
(en)
|
2004-06-18 |
2009-10-01 |
Ambrx, Inc. |
Novel antigen-binding polypeptides and their uses
|
EP1758999B1
(fr)
|
2004-06-22 |
2011-03-09 |
The Board Of Trustees Of The University Of Illinois |
Procedes pour inhiber la proliferation des cellules tumorales avec foxm1 arnsi
|
KR101239542B1
(ko)
|
2004-06-24 |
2013-03-07 |
바이오겐 아이덱 엠에이 인코포레이티드 |
탈수초화를 수반하는 병의 치료
|
US20080280973A1
(en)
*
|
2004-06-28 |
2008-11-13 |
Wender Paul A |
Laulimalide Analogues as Therapeutic Agents
|
US20060004185A1
(en)
*
|
2004-07-01 |
2006-01-05 |
Leese Richard A |
Peptide antibiotics and peptide intermediates for their prepartion
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
CA2576193A1
(fr)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Influence du taj sur les fonctions neuronales
|
CA2575988C
(fr)
*
|
2004-08-04 |
2014-02-18 |
Brookwood Pharmaceuticals, Inc. |
Procede de production de systemes d'administration, et systemes d'administration
|
EP2336177A1
(fr)
|
2004-08-04 |
2011-06-22 |
Amgen, Inc |
anticorps anti-DKK-1
|
KR101231856B1
(ko)
|
2004-08-12 |
2013-02-08 |
큐피에스 엘엘씨 |
생물학적 활성 화합물의 제어 방출 전달용 약학 조성물
|
US8299083B2
(en)
|
2004-08-17 |
2012-10-30 |
The Johns Hopkins University |
PDE5 inhibitor compositions and methods for treating cardiac indications
|
WO2006029406A2
(fr)
*
|
2004-09-09 |
2006-03-16 |
Stryker Corporation |
Methodes de traitement de tumeurs osseuses
|
CA2581287C
(fr)
|
2004-09-17 |
2015-08-25 |
Durect Corporation |
Systeme de distribution commandee
|
CA2583061C
(fr)
|
2004-10-06 |
2015-02-17 |
Kwang Guan Tay |
Methode de production d'anticorps
|
FR2876379B1
(fr)
*
|
2004-10-08 |
2008-09-05 |
Isochem Sa |
Procede de polymerisation des o-carboxy anhydrides
|
WO2006041048A1
(fr)
|
2004-10-15 |
2006-04-20 |
Mie University |
Agent de régulation de la régénération/réparation du foie
|
EP1824886B1
(fr)
|
2004-11-17 |
2010-12-22 |
Amgen Inc. |
Anticorps monoclonaux entierement humains diriges contre l'il-13
|
US7619007B2
(en)
|
2004-11-23 |
2009-11-17 |
Adamas Pharmaceuticals, Inc. |
Method and composition for administering an NMDA receptor antagonist to a subject
|
GB0425854D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Astrazeneca Ab |
Therapeutic treatment
|
ATE504602T1
(de)
|
2004-12-20 |
2011-04-15 |
Amgen Fremont Inc |
Für humane matriptase spezifische bindungsproteine
|
RU2394839C2
(ru)
|
2004-12-21 |
2010-07-20 |
Астразенека Аб |
Антитела против ангиопоэтина-2 и их применение
|
BRPI0519430A2
(pt)
|
2004-12-22 |
2009-02-10 |
Ambrx Inc |
hormânio do crescimento humano modificado
|
MX2007007590A
(es)
|
2004-12-22 |
2007-12-10 |
Ambrx Inc |
Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
|
EP1835885A1
(fr)
*
|
2004-12-23 |
2007-09-26 |
Durect Corporation |
IMPLANTS POLYMÉRIQUES, CONTENANT DE PRÉFÉRENCE UN MÉLANGE DE PEG ET DE PLG, POUR UNE LIBÉRATION CONTRÔLÉE D'UNE GnRH
|
AU2005321940B2
(en)
*
|
2004-12-29 |
2012-04-19 |
Mannkind Corporation |
Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
|
EP1851245B1
(fr)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Anticorps dirigés contre l'interleukine-1 beta
|
WO2007059082A1
(fr)
|
2005-11-10 |
2007-05-24 |
Curagen Corporation |
Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
|
DE602006016934D1
(de)
*
|
2005-04-06 |
2010-10-28 |
Adamas Pharmaceuticals Inc |
Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
|
EP2824183B1
(fr)
|
2005-04-08 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Procédé pour la production d'anticorps bispécifiques
|
WO2006112737A1
(fr)
*
|
2005-04-20 |
2006-10-26 |
Protemix Discovery Limited |
Vesiculines
|
CA2605000A1
(fr)
*
|
2005-04-25 |
2006-11-02 |
Amgen Inc. |
Compositions a liberation prolongee comprenant des peptides et leurs utilisations
|
ATE382337T1
(de)
|
2005-04-28 |
2008-01-15 |
Nipro Corp |
Bioabsorbierbare pharmazeutische zusammensetzung enthaltend einen plga-copolymer
|
CA2605508A1
(fr)
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blocage de pin1 pour empecher le production de cytokines par les cellules immunitaires activees
|
ES2614080T3
(es)
*
|
2005-05-17 |
2017-05-29 |
Sarcode Bioscience Inc. |
Composiciones y métodos para el tratamiento de trastornos oculares
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
KR101367544B1
(ko)
|
2005-06-10 |
2014-02-26 |
추가이 세이야쿠 가부시키가이샤 |
메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
|
US20090028854A1
(en)
|
2005-06-10 |
2009-01-29 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
BRPI0611901A2
(pt)
|
2005-06-14 |
2012-08-28 |
Amgen, Inc |
composição, liofilizado, kit, e, processo para preparar uma composição
|
PL2163562T3
(pl)
|
2005-06-21 |
2014-03-31 |
Xoma Us Llc |
Przeciwciała wiążące IL-1 beta i ich fragmenty
|
RS53058B
(en)
|
2005-07-08 |
2014-04-30 |
Biogen Idec Ma Inc. |
SP35 ANTIBODIES AND THEIR APPLICATIONS
|
SI1915398T1
(sl)
|
2005-07-18 |
2016-07-29 |
Amgen Inc. |
Humana nevtralizacijska protitelesa proti b7rp1
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
AU2006272497B2
(en)
|
2005-07-27 |
2012-07-19 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
WO2007030519A2
(fr)
|
2005-09-08 |
2007-03-15 |
Trustees Of Tufts College |
Analogues de glp-1 stabilises
|
KR20080074108A
(ko)
|
2005-09-27 |
2008-08-12 |
스템 셀 테라퓨틱스 코포레이션 |
프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
|
EP1937262B1
(fr)
|
2005-09-29 |
2019-05-08 |
Ipsen Pharma |
Composition pour l'utilisation dans le traitement de la dysmotilité gastrointestinale
|
US8852638B2
(en)
|
2005-09-30 |
2014-10-07 |
Durect Corporation |
Sustained release small molecule drug formulation
|
EP3037544A1
(fr)
|
2005-10-13 |
2016-06-29 |
Human Genome Sciences, Inc. |
Procedes et compositions destinees au traitement de patients atteints de lupus erythematosus systémique positifs pour des auto-anticorps
|
EP1941907B1
(fr)
|
2005-10-14 |
2016-03-23 |
Fukuoka University |
Inhibiteur de dysfonctionnement d'îlots transplantés dans un transplant d'îlots
|
KR101239051B1
(ko)
|
2005-10-21 |
2013-03-04 |
추가이 세이야쿠 가부시키가이샤 |
심장질환 치료제
|
CA2628451A1
(fr)
|
2005-11-04 |
2007-05-18 |
Biogen Idec Ma Inc. |
Procedes favorisant la croissance des neurites et la survie des neurones dopaminergiques
|
US7942867B2
(en)
*
|
2005-11-09 |
2011-05-17 |
The Invention Science Fund I, Llc |
Remotely controlled substance delivery device
|
US8128934B2
(en)
|
2005-11-14 |
2012-03-06 |
Ribomic, Inc. |
Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
|
PE20070684A1
(es)
|
2005-11-14 |
2007-08-06 |
Amgen Inc |
MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
EP2339014B1
(fr)
|
2005-11-16 |
2015-05-27 |
Ambrx, Inc. |
Procédés et compositions comprenant des acides aminés non naturels
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
US20100003287A1
(en)
|
2005-12-01 |
2010-01-07 |
The Provost, Fellows And Scholars Of The Coll. Of The Holy And Undivided Trinity Of Queen Elizabeth |
Compositions and Methods Relating to Treatment of Cancer and Infectious Diseases
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
EP2543384A3
(fr)
|
2005-12-02 |
2013-04-10 |
Biogen Idec MA Inc. |
Traitement des conditions impliquant la démyélinisation
|
WO2008024128A2
(fr)
|
2005-12-05 |
2008-02-28 |
Simon Delagrave |
Domaines pdz variants de boucle en tant que produits biothérapeutiques, produits diagnostiques et réactifs de recherche
|
WO2007066313A2
(fr)
|
2005-12-05 |
2007-06-14 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
Compositions et procedes de modulation d’une reponse immunitaire
|
CN105753983A
(zh)
|
2005-12-13 |
2016-07-13 |
阿斯利康(瑞典)有限公司 |
胰岛素样生长因子特异性结合蛋白及其用途
|
PL1969003T3
(pl)
|
2005-12-14 |
2011-05-31 |
Herantis Pharma Plc |
Zastosowanie białka czynnika neurotroficznego
|
CN101370519B
(zh)
|
2005-12-15 |
2013-07-24 |
阿斯利康(瑞典)有限公司 |
治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合
|
RU2457854C2
(ru)
|
2005-12-30 |
2012-08-10 |
Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед |
Длительное высвобождение нейрегулина для улучшения сердечной функции
|
US20070154546A1
(en)
*
|
2005-12-30 |
2007-07-05 |
Zhang Jack Y |
Sustained release pharmaceutical compositions
|
CA2636600A1
(fr)
|
2006-01-17 |
2007-07-26 |
Dnavec Corporation |
Nouveau systeme d'expression de proteines
|
WO2007084460A2
(fr)
*
|
2006-01-18 |
2007-07-26 |
Qps, Llc |
Compositions pharmaceutiques a stabilite amelioree
|
CA2913655A1
(fr)
|
2006-01-27 |
2007-08-09 |
Biogen Ma Inc. |
Antagonistes des recepteurs nogo
|
CN101370521A
(zh)
|
2006-01-27 |
2009-02-18 |
学校法人庆应义塾 |
伴有脉络膜血管生成的疾病的治疗药
|
US7756524B1
(en)
|
2006-01-31 |
2010-07-13 |
Nextel Communications Inc. |
System and method for partially count-based allocation of vocoder resources
|
CU23388B6
(es)
*
|
2006-01-31 |
2009-07-16 |
Ct Ingenieria Genetica Biotech |
Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
|
US20070178138A1
(en)
*
|
2006-02-01 |
2007-08-02 |
Allergan, Inc. |
Biodegradable non-opthalmic implants and related methods
|
CN101415723B
(zh)
*
|
2006-02-02 |
2014-06-25 |
特里梅里斯公司 |
具有改良生物学特性的hiv融合抑制肽
|
WO2007092314A2
(fr)
|
2006-02-02 |
2007-08-16 |
Verenium Corporation |
Estérases, acides nucléiques apparentés et procédés associés
|
CA2643502A1
(fr)
*
|
2006-03-17 |
2007-09-27 |
Stem Cell Therapeutics Corp. |
Regimes de dosage de lh ou hcg et epo pour le traitement de troubles neurologiques
|
EP1837014A1
(fr)
*
|
2006-03-21 |
2007-09-26 |
Hexal Ag |
Implants sous-cutanés contenant un polymère de polylactide résistant à la dégradation et un analogue de la LH-RH
|
CA2648644C
(fr)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Promoteur de regeneration musculaire
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CA2652549A1
(fr)
|
2006-05-17 |
2007-12-13 |
Stryker Corporation |
Procede pour traiter des defauts cartilagineux a l'aide d'uncomplexe de proteine morphogenique soluble
|
WO2007136679A2
(fr)
|
2006-05-17 |
2007-11-29 |
Ludwig Institute For Cancer Research |
Cibler la régulation du vegf-b des transporteurs d'acides gras afin de moduler les maladies humaines
|
US7403325B2
(en)
*
|
2006-05-19 |
2008-07-22 |
Xerox Corporation |
Electrophoretic display device
|
WO2007137245A2
(fr)
*
|
2006-05-22 |
2007-11-29 |
Columbia University |
Systèmes d'échange microfluidique sans membrane et procédé associé, dans lesquels les effluents d'un fluide d'extraction sont filtrés
|
WO2007139589A1
(fr)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Modulateurs des récepteurs de glp-1 à libération prolongée
|
WO2007143121A2
(fr)
|
2006-06-01 |
2007-12-13 |
President And Fellows Of Harvard College |
Purification d'un anticorps actif de manière bivalente en utilisant un procédé non chromatographique
|
AR061317A1
(es)
|
2006-06-08 |
2008-08-20 |
Chugai Pharmaceutical Co Ltd |
Agentes para prevenir o tratar enfermedades inflamatorias
|
GB0611405D0
(en)
|
2006-06-09 |
2006-07-19 |
Univ Belfast |
FKBP-L: A novel inhibitor of angiogenesis
|
EP2046435A4
(fr)
*
|
2006-07-13 |
2012-06-27 |
Medtronic Inc |
Procédés et formulations pour la délivrance locale optimale de thérapie cellulaire via des procédures à invasion minimale
|
CA2657385A1
(fr)
|
2006-07-13 |
2008-01-17 |
Naoki Kimura |
Inducteur de mort cellulaire
|
US8025881B2
(en)
|
2006-07-21 |
2011-09-27 |
Chugai Seiyaku Kabushiki Kaisha |
BMP antibodies and methods of treating kidney disease using the same
|
CA2658786A1
(fr)
|
2006-07-28 |
2008-01-31 |
Children's Memorial Hospital |
Procedes d'inhibition de l'agressivite des cellules tumorales a l'aide du microenvironnement des cellules souches embryonnaires humaines
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
EP2054437A2
(fr)
|
2006-08-07 |
2009-05-06 |
Teva Biopharmaceuticals USA, Inc. |
Protéines de fusion d'albumine et d'insuline
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Fc 스캐폴드 및 그의 용도
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
EP2311481A3
(fr)
|
2006-10-20 |
2013-10-16 |
Biogen Idec MA Inc. |
Traitement de maladies démyélinisantes avec le recepteur soluble de la lymphotoxine beta
|
US8338376B2
(en)
|
2006-10-20 |
2012-12-25 |
Biogen Idec Ma Inc. |
Compositions comprising variant LT-B-R-IG fusion proteins
|
AU2007325918B2
(en)
|
2006-11-03 |
2013-10-17 |
Durect Corporation |
Transdermal delivery systems comprising bupivacaine
|
AU2007319359A1
(en)
|
2006-11-14 |
2008-05-22 |
Genentech, Inc. |
Modulators of neuronal regeneration
|
BRPI0720218A2
(pt)
|
2006-12-08 |
2013-12-24 |
Lexicon Pharmaceuticals Inc |
Anticorpos monoclonais contra angptl3
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
NZ577281A
(en)
|
2006-12-18 |
2011-12-22 |
Takeda Pharmaceutical |
Sustained-release composition and method for producing the same
|
CN103405768A
(zh)
|
2006-12-20 |
2013-11-27 |
爱克索马技术有限公司 |
用于治疗IL-1β相关疾病的方法
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
EP2740744B1
(fr)
|
2007-01-09 |
2018-03-28 |
Biogen MA Inc. |
Anticorps Sp35 et utilisations associées
|
CN101646459B
(zh)
|
2007-01-23 |
2014-02-12 |
国立大学法人信州大学 |
慢性排斥反应抑制剂
|
MX2009008178A
(es)
|
2007-02-02 |
2009-10-26 |
Biogen Idec Inc |
Uso de semaforina 6a para promover la mielinizacion y la diferenciacion de oligodendrocitos.
|
US7947646B2
(en)
|
2007-03-06 |
2011-05-24 |
Amgen Inc. |
Variant activin receptor polypeptides
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
BRPI0809583B1
(pt)
|
2007-03-30 |
2022-02-22 |
Ambrx, Inc |
Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
|
US20090068243A1
(en)
*
|
2007-04-03 |
2009-03-12 |
Brian Bray |
Novel formulations for delivery of antiviral peptide therapeutics
|
US9023395B2
(en)
*
|
2007-04-13 |
2015-05-05 |
University Of North Texas Health Science Center At Fort Worth |
Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics
|
US20100290982A1
(en)
*
|
2007-04-13 |
2010-11-18 |
University Of North Texas Health Science Center At Fort Worth |
Solid in oil/water emulsion-diffusion-evaporation formulation for preparing curcumin-loaded plga nanoparticles
|
WO2008140026A1
(fr)
|
2007-05-11 |
2008-11-20 |
Bizen Chemical Co., Ltd. |
Antagoniste inédit du récepteur des leucotriènes
|
JP5599705B2
(ja)
*
|
2007-05-18 |
2014-10-01 |
デュレクト コーポレーション |
改良されたデポー製剤
|
BRPI0811319A2
(pt)
|
2007-05-25 |
2015-02-10 |
Tolmar Therapeutics Inc |
Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
|
EP2170930B3
(fr)
|
2007-06-04 |
2013-10-02 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
GB0710976D0
(en)
|
2007-06-07 |
2007-07-18 |
Bioalvo |
Am Screening method
|
JP2010529999A
(ja)
|
2007-06-14 |
2010-09-02 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
抗体製剤
|
CA2692171C
(fr)
|
2007-06-22 |
2019-10-22 |
Randolph Watnick |
Procedes et utilisations de prosaposine
|
WO2011084685A2
(fr)
|
2009-12-17 |
2011-07-14 |
Children's Medical Center Corporation |
Peptides dérivés de saposine a et utilisations de ceux-ci
|
US20110206673A1
(en)
|
2007-06-27 |
2011-08-25 |
Liu Dongxu |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
DE102007036101A1
(de)
*
|
2007-08-01 |
2009-02-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue glycolidreiche Copolymere
|
TW200916113A
(en)
|
2007-08-08 |
2009-04-16 |
Sod Conseils Rech Applic |
Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
|
JP5718640B2
(ja)
|
2007-08-21 |
2015-05-13 |
アムジエン・インコーポレーテツド |
ヒトc−fms抗原結合性タンパク質
|
EP2615113A3
(fr)
|
2007-08-23 |
2013-11-13 |
Amgen Inc. |
Protéines de liaison à un antigène pour proprotéine convertase subtilisine kexine de type 9 (PCSK9)
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2040075A1
(fr)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Composés et marqueurs pour la diffusion Raman de surface améliorée
|
KR20100080812A
(ko)
*
|
2007-09-25 |
2010-07-12 |
트라이머리스, 인코퍼레이티드 |
치료용 항-hiv 펩티드의 합성 방법
|
EP2207809B1
(fr)
|
2007-09-26 |
2013-07-03 |
U3 Pharma GmbH |
Protéines de liaison avec l'antigène du facteur de croissance de type facteur de croissance épidermique se liant à l'héparine
|
KR101601986B1
(ko)
|
2007-10-02 |
2016-03-17 |
추가이 세이야쿠 가부시키가이샤 |
인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
|
WO2009044402A1
(fr)
*
|
2007-10-02 |
2009-04-09 |
Ariel - University Research And Development Company Ltd. |
Endocannabinoïdes pour améliorer la croissance et le développement chez les nourrissons
|
WO2009046299A2
(fr)
*
|
2007-10-04 |
2009-04-09 |
Boston Scientific Scimed, Inc |
Forme retard implantable pour un système antidouleur d'administration de médicament intrarachidien
|
EP3797775A1
(fr)
|
2007-10-19 |
2021-03-31 |
Novartis AG |
Compositions et procédés pour le traitement de la rétinopathie diabétique
|
WO2009064442A1
(fr)
*
|
2007-11-13 |
2009-05-22 |
Brookwood Pharmaceuticals, Inc. |
Terpolymères visqueux en tant que plateforme de délivrance de médicaments
|
CA2705582A1
(fr)
|
2007-11-16 |
2009-05-22 |
The Rockefeller University |
Anticorps specifiques de la forme de protofibrille de proteine beta-amyloide
|
CN101918026B
(zh)
|
2007-11-20 |
2016-03-02 |
Ambrx公司 |
经修饰胰岛素多肽和其用途
|
TWI441649B
(zh)
|
2007-12-05 |
2014-06-21 |
Chugai Pharmaceutical Co Ltd |
Use of anti-NR10 monoclonal antibody with neutralizing activity against NR10 in the manufacture of prophylactic or therapeutic agents for pruritus
|
BRPI0821110B8
(pt)
|
2007-12-05 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
|
JP2011506319A
(ja)
|
2007-12-06 |
2011-03-03 |
デュレクト コーポレーション |
疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
|
EP2241333A1
(fr)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Agent thérapeutique pour une leucémie mll et une leucémie moz dont la cible moléculaire est le récepteur m-csf, et son utilisation
|
US8637029B2
(en)
|
2007-12-20 |
2014-01-28 |
Xoma Technology Ltd. |
Methods for the treatment of gout
|
US20090181068A1
(en)
*
|
2008-01-14 |
2009-07-16 |
Dunn Richard L |
Low Viscosity Liquid Polymeric Delivery System
|
CA2714594A1
(fr)
*
|
2008-02-04 |
2009-08-13 |
Edward F. Leonard |
Dispositifs de separation de fluide, systemes et procedes
|
JP5702150B2
(ja)
|
2008-02-08 |
2015-04-15 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾されているレプチンポリペプチドおよびそれらの使用
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
PT2251006T
(pt)
*
|
2008-02-22 |
2017-10-13 |
Toray Industries |
Micropartículas e suas composições farmacêuticas
|
WO2009139817A2
(fr)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Produit pharmaceutique cristallin et ses procédés de préparation et d'utilisation
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
JP2011522828A
(ja)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
|
WO2009148148A1
(fr)
|
2008-06-05 |
2009-12-10 |
国立がんセンター総長が代表する日本国 |
Inhibiteur de neuro-invasion
|
TR201904041T4
(tr)
|
2008-06-09 |
2019-04-22 |
Max Planck Gesellschaft |
Protein agregasyonu ile bağlantılı hastalıklarda ve/veya nörodejeneratif hastalıklarda rol oynayan proteinlerin agregasyonunu inhibe etmeye yönelik ilaçlar.
|
EP2307456B1
(fr)
|
2008-06-27 |
2014-10-15 |
Amgen Inc. |
Inhibition de l ang-2 pour traiter la sclérose en plaques
|
DK2982695T3
(da)
|
2008-07-09 |
2019-05-13 |
Biogen Ma Inc |
Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
UA103774C2
(uk)
|
2008-07-23 |
2013-11-25 |
Амбркс, Інк. |
Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
|
AU2009277252B2
(en)
|
2008-07-30 |
2014-01-16 |
Mesynthes Limited |
Tissue scaffolds derived from forestomach extracellular matrix
|
US8153391B2
(en)
|
2008-08-29 |
2012-04-10 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8357503B2
(en)
|
2008-08-29 |
2013-01-22 |
Bunge Oils, Inc. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
US8198062B2
(en)
|
2008-08-29 |
2012-06-12 |
Dsm Ip Assets B.V. |
Hydrolases, nucleic acids encoding them and methods for making and using them
|
CN104306967A
(zh)
|
2008-09-10 |
2015-01-28 |
霍夫曼-拉罗奇有限公司 |
抑制眼部血管生成的方法
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
MX343802B
(es)
|
2008-09-26 |
2016-11-23 |
Ambrx Inc |
Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
|
CN107022020A
(zh)
|
2008-09-26 |
2017-08-08 |
Ambrx公司 |
修饰的动物促红细胞生成素多肽和其用途
|
MX341149B
(es)
|
2008-10-10 |
2016-08-09 |
Amgen Inc |
Mutantes fgf21 y uso de los mismos.
|
CN102317314A
(zh)
|
2008-10-10 |
2012-01-11 |
阿纳福公司 |
结合trail-r1和trail-r2的多肽
|
MX2011004306A
(es)
|
2008-10-22 |
2011-07-28 |
Genentech Inc |
Modulacion de degeneracion de axones.
|
EP4104821A1
(fr)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulations de molécules de liaison d'antigène monodomaines
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
CA2744120A1
(fr)
|
2008-11-17 |
2010-05-20 |
The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, |
Peptide de proteine a46 de virus de la vaccine et utilisation de celui-ci
|
BRPI0920962A2
(pt)
|
2008-11-26 |
2016-07-12 |
Amgen Inc |
variantes de polipeptídeos receptores de activina iib e usos dos mesmos
|
WO2010070136A2
(fr)
|
2008-12-19 |
2010-06-24 |
Centre de Recherche Public de la Santé |
Nouveaux allergènes de caviidae et leurs utilisations
|
US20110312872A1
(en)
|
2008-12-22 |
2011-12-22 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
US8951546B2
(en)
|
2008-12-23 |
2015-02-10 |
Surmodics Pharmaceuticals, Inc. |
Flexible implantable composites and implants comprising same
|
AU2009331528A1
(en)
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
AR074874A1
(es)
|
2008-12-23 |
2011-02-16 |
Biosource Pharm Inc |
Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
US9415197B2
(en)
|
2008-12-23 |
2016-08-16 |
Surmodics, Inc. |
Implantable suction cup composites and implants comprising same
|
US20100158978A1
(en)
*
|
2008-12-23 |
2010-06-24 |
Peter Markland |
Bioactive spray coating compositions and methods of making and uses thereof
|
US8974808B2
(en)
*
|
2008-12-23 |
2015-03-10 |
Surmodics, Inc. |
Elastic implantable composites and implants comprising same
|
US20100168807A1
(en)
*
|
2008-12-23 |
2010-07-01 |
Burton Kevin W |
Bioactive terpolymer compositions and methods of making and using same
|
EP2390261A4
(fr)
|
2009-01-20 |
2012-11-14 |
Hanall Biopharma Co Ltd |
Fragment polypeptidique de thrombopoïétine humaine modifié et son procédé de fabrication
|
WO2010085609A2
(fr)
*
|
2009-01-23 |
2010-07-29 |
Surmodics Pharmaceuticals, Inc. |
Système à libération contrôlée de mélange polymères
|
EP2389413A1
(fr)
*
|
2009-01-23 |
2011-11-30 |
Surmodics Pharmaceuticals, Inc. |
Mélanges de polymères comprenant des polymères ayant différentes unités non répétitives et leurs procédés de fabrication et d'utilisation
|
WO2010093993A2
(fr)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
|
WO2010092109A2
(fr)
|
2009-02-13 |
2010-08-19 |
Novartis Ag |
Molécule d'acide nucléique d'un agrégat biosynthétique codant pour des synthases peptidiques non ribosomales et leurs utilisations
|
TW201031436A
(en)
*
|
2009-02-16 |
2010-09-01 |
Univ Nat Taiwan |
Pharmaceutical composition for inhalation delivery and fabrication method thereof
|
EP2398467A1
(fr)
|
2009-02-18 |
2011-12-28 |
Bayer Pharma Aktiengesellschaft |
Particules comprenant de la drospirénone encapsulée dans un polymère
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
CA2760674A1
(fr)
|
2009-05-05 |
2010-11-11 |
Amgen Inc. |
Mutants de fgf21 et leurs utilisations
|
PE20120358A1
(es)
|
2009-05-05 |
2012-04-26 |
Amgen Inc |
Mutantes fgf21 y usos de los mismos
|
EP2260857A1
(fr)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Nouvelles applications de HIP/PAP ou dérivés associés
|
WO2010144797A2
(fr)
|
2009-06-12 |
2010-12-16 |
Vaccine Technologies, Incorporated |
Vaccins contre la grippe avec immunogénicité accrue et leurs utilisations
|
IN2012DN00352A
(fr)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
AU2010262927A1
(en)
|
2009-06-17 |
2012-01-19 |
Amgen Inc. |
Chimeric FGF19 polypeptides and uses thereof
|
WO2011010131A1
(fr)
|
2009-07-21 |
2011-01-27 |
Astrazeneca Ab |
Compositions comprenant un oxoisoquinoléin-méthylbenzamide et un polymère
|
WO2011010132A1
(fr)
|
2009-07-21 |
2011-01-27 |
Astrazeneca Ab |
Composé 600
|
AU2010278067B2
(en)
|
2009-07-31 |
2016-10-27 |
Shin Maeda |
Cancer metastasis inhibitor
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
EP2305285A1
(fr)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Supports et procédés pour traiter les conditions ischémiques
|
EP2305810A1
(fr)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miARN pour le traitement de la fibrose
|
EP2308478A1
(fr)
|
2009-10-06 |
2011-04-13 |
Abbott GmbH & Co. KG |
Système de libération prolongée d'agents bloquants des canaux calciques
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
WO2011046457A1
(fr)
|
2009-10-16 |
2011-04-21 |
Auckland Uniservices Limited |
Utilisations antinéoplasiques d'antagonistes d'artémine
|
WO2011049350A2
(fr)
|
2009-10-19 |
2011-04-28 |
한올바이오파마주식회사 |
Polypeptide modifié du récepteur 1 du facteur humain de nécrose tumorale ou son fragment, et méthode de préparation associée
|
WO2011050175A1
(fr)
|
2009-10-21 |
2011-04-28 |
Sarcode Corporation |
Agent pharmaceutique cristallin et procédés de préparation et utilisation de celui-ci
|
AU2010310589A1
(en)
|
2009-10-22 |
2012-05-10 |
Genentech, Inc. |
Modulation of axon degeneration
|
US8729058B2
(en)
|
2009-10-27 |
2014-05-20 |
Michael Zasloff |
Methods and compositions for treating and preventing viral infections
|
CN106399276B
(zh)
|
2009-11-02 |
2021-08-10 |
华盛顿大学 |
治疗性核酸酶组合物和方法
|
EP2742949A1
(fr)
|
2009-11-13 |
2014-06-18 |
Puget Sound Blood Center |
Épitope variante du facteur VIII réduisant l'immunogénicité des lymphocytes B
|
RS60033B1
(sr)
|
2009-11-24 |
2020-04-30 |
Medimmune Ltd |
Ciljano vezujući agensi usmereni na b7-h1
|
WO2011066260A2
(fr)
|
2009-11-25 |
2011-06-03 |
Michael Zasloff |
Formulations comprenant des aminostérols
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
AU2010325960C1
(en)
|
2009-12-02 |
2015-08-06 |
Adamas Pharma, Llc |
Amantadine compositions and methods of use
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
JP5878477B2
(ja)
|
2010-01-15 |
2016-03-08 |
ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュー ジャージー |
骨の治癒を加速するためのバナジウム化合物の使用
|
US20130053438A1
(en)
|
2010-01-19 |
2013-02-28 |
Universitat Innsbruck |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
CA2788021A1
(fr)
|
2010-01-27 |
2011-08-04 |
Children's Medical Center Corporation |
Fragments proangiogenes de prominine 1 et utilisations de ceux-ci
|
JP2013517782A
(ja)
|
2010-01-28 |
2013-05-20 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
因子vii融合ポリペプチド
|
EP2533859B1
(fr)
|
2010-02-10 |
2016-04-06 |
Nayacure Therapeutics Ltd |
Compositions pharmaceutiques pour le traitement et la prévention du cancer
|
GB201003559D0
(en)
|
2010-03-03 |
2010-04-21 |
Proteo Biotech Ag |
Novel use of elafin
|
WO2011112906A2
(fr)
|
2010-03-12 |
2011-09-15 |
Children's Medical Center Corporation |
Nouveaux immunogènes et procédés pour la découverte et le dépistage de ceux-ci
|
US20130052197A1
(en)
|
2010-03-26 |
2013-02-28 |
The University Of Tokushima |
Novel anti-cd98 antibody and use thereof
|
MX2012011986A
(es)
|
2010-04-15 |
2013-03-05 |
Amgen Inc |
RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
|
WO2011131626A1
(fr)
|
2010-04-19 |
2011-10-27 |
Medizinische Universität Innsbruck |
Tmem195 code pour l'activité alkylglycérol monooxygénase dépendante de la tétrahydrobioptérine
|
JP5894574B2
(ja)
|
2010-04-22 |
2016-03-30 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
GB201007531D0
(en)
|
2010-05-05 |
2010-06-23 |
Imp Innovations Ltd |
Composition
|
EP2566964B1
(fr)
|
2010-05-07 |
2016-10-19 |
Centre National De La Recherche Scientifique |
Inducteurs de l'ucp1 (thermogenin) destinés à une utilisation dans le traitement des maladies de l'homeostasie energetique
|
US9273316B2
(en)
|
2010-05-21 |
2016-03-01 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
EP2578233B1
(fr)
|
2010-05-28 |
2017-04-26 |
National Cancer Center |
Agent thérapeutique contre le cancer du pancréas
|
HRP20221490T1
(hr)
|
2010-05-28 |
2023-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Poboljšanje antitumorskog odgovora t stanice
|
EP2579892A2
(fr)
|
2010-06-09 |
2013-04-17 |
Vaccine Technologies, Incorporated |
Immunisation thérapeutique chez des patients infectés par le vih recevant un traitement antirétroviral stable
|
CA2802761C
(fr)
|
2010-06-16 |
2017-01-03 |
Endorecherche, Inc. |
Methodes de traitement prophylactique ou therapeutique de maladies liees aux estrogenes
|
CA2802635A1
(fr)
|
2010-06-18 |
2011-12-22 |
Xiberscience Gmbh |
Peptides en tant qu'agents actifs pour stabiliser des barrieres biologiques
|
US8415307B1
(en)
|
2010-06-23 |
2013-04-09 |
Biosource Pharm, Inc. |
Antibiotic compositions for the treatment of gram negative infections
|
EP2585092A1
(fr)
|
2010-06-24 |
2013-05-01 |
Torrent Pharmaceuticals Limited |
Composition pharmaceutique contenant de la goséréline pour un implant in situ
|
US9211175B2
(en)
|
2010-07-08 |
2015-12-15 |
Covidien Lp |
Self-detachable medical devices
|
FR2962646B1
(fr)
|
2010-07-16 |
2012-06-22 |
Sofradim Production |
Prothese avec element radio-opaque
|
CN108314733A
(zh)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
UY33517A
(es)
|
2010-07-19 |
2012-02-29 |
Astrazeneca Ab |
Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
MA34521B1
(fr)
|
2010-08-17 |
2013-09-02 |
Ambrx Inc |
Polypeptides de relaxine modifiés et leurs utilisations
|
JP5976651B2
(ja)
|
2010-08-30 |
2016-08-24 |
サーモディクス ファーマシューティカルズ, インコーポレイテッド |
感圧接着剤としての生分解性ターポリマーおよびターポリマー配合物
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
DK2623592T3
(da)
|
2010-09-28 |
2019-08-19 |
Nb Health Laboratory Co Ltd |
Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer
|
CA2813304A1
(fr)
|
2010-10-01 |
2012-04-05 |
Biogen Idec Ma Inc. |
Interferon-beta utilise en tant que monotherapie ou en combinaison avec d'autres cancerotherapies
|
US9572907B2
(en)
|
2010-10-01 |
2017-02-21 |
Covidien Lp |
Implantable polymeric films
|
US8920867B2
(en)
|
2010-10-19 |
2014-12-30 |
Covidien Lp |
Methods of forming self-supporting films for delivery of therapeutic agents
|
US9861590B2
(en)
|
2010-10-19 |
2018-01-09 |
Covidien Lp |
Self-supporting films for delivery of therapeutic agents
|
US8632839B2
(en)
|
2010-10-19 |
2014-01-21 |
Covidien Lp |
Methods of forming self-supporting films for delivery of therapeutic agents
|
KR20140014077A
(ko)
|
2010-10-25 |
2014-02-05 |
리전츠 오브 더 유니버스티 오브 미네소타 |
교모세포종의 치료를 위한 치료 조성물
|
EP2632951B1
(fr)
|
2010-10-27 |
2017-08-02 |
Amgen Inc. |
Anticorps anti-dkk1 et leurs procédés d'utilisation
|
JP6189215B2
(ja)
|
2010-11-01 |
2017-08-30 |
ペプチメッド, インコーポレイテッド |
細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物
|
TWI452136B
(zh)
|
2010-11-17 |
2014-09-11 |
中外製藥股份有限公司 |
A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
|
GB201019467D0
(en)
|
2010-11-17 |
2010-12-29 |
Biotecnol Sa |
Therapeutic agent
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
RU2013123793A
(ru)
|
2010-11-24 |
2014-12-27 |
Лексикон Фармасьютикалз, Инк. |
Антитела, связывающиеся с notum пектинацетилэстеразой
|
TWI638833B
(zh)
|
2010-11-30 |
2018-10-21 |
中外製藥股份有限公司 |
細胞傷害誘導治療劑
|
JP5819439B2
(ja)
|
2010-12-23 |
2015-11-24 |
ハノル バイオファーマ カンパニー リミテッド |
修飾されたヒト腫瘍壊死因子受容体−1ポリペプチドまたはその断片及びその製造方法
|
WO2012092539A2
(fr)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Anticorps contre dll4 et leurs utilisations
|
US9144634B2
(en)
|
2011-01-14 |
2015-09-29 |
Covidien Lp |
Medical device with intrapore films
|
US9315566B2
(en)
|
2011-01-24 |
2016-04-19 |
National University Of Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
AU2012209466C1
(en)
|
2011-01-27 |
2016-06-23 |
Neuren Pharmaceuticals Limited |
Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
|
EA201391248A1
(ru)
|
2011-03-01 |
2014-05-30 |
Эмджен Инк. |
Биспецифические связывающие агенты
|
MX2013010185A
(es)
|
2011-03-10 |
2014-02-17 |
Genentech Inc |
Tratamiento de alteraciones con funcion de barrera vascular alterada.
|
US10059746B2
(en)
|
2011-04-04 |
2018-08-28 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
US8628773B2
(en)
|
2011-04-07 |
2014-01-14 |
Amgen Inc. |
Antigen binding proteins
|
JP5977814B2
(ja)
|
2011-04-08 |
2016-08-24 |
アムジエン・インコーポレーテツド |
増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法
|
KR101539313B1
(ko)
|
2011-04-25 |
2015-07-24 |
산동 루예 파마슈티칼 컴파니 리미티드 |
리스페리돈의 서방성 미소구체 조성물
|
KR102596953B1
(ko)
|
2011-04-29 |
2023-11-02 |
유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 |
치료적 뉴클레아제 조성물 및 방법
|
JP2014513128A
(ja)
|
2011-05-03 |
2014-05-29 |
ジェネンテック, インコーポレイテッド |
血管破壊剤とその使用
|
AU2012250776B2
(en)
|
2011-05-04 |
2017-06-15 |
Balance Therapeutics, Inc. |
Pentylenetetrazole derivatives
|
AU2012254160A1
(en)
|
2011-05-10 |
2013-11-21 |
Amgen Inc. |
Method of identifying compounds that specifically modulate the interaction of FGFR1 and beta-Klotho
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
BR112013028887B1
(pt)
|
2011-05-11 |
2020-10-06 |
Children's Medical Center Corporation |
Composição imunogênica apresentando múltiplos antígenos, e métodos e usos dos mesmos
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
CN103917093B
(zh)
|
2011-06-14 |
2017-08-11 |
比卡姆药品公司 |
视蛋白结合配体、组合物及使用方法
|
CA2838340A1
(fr)
|
2011-06-17 |
2012-12-20 |
Amgen Inc. |
Methode de traitement ou d'amelioration de troubles metaboliques a l'aide de clec-2
|
FR2977790B1
(fr)
|
2011-07-13 |
2013-07-19 |
Sofradim Production |
Prothese pour hernie ombilicale
|
WO2013016220A1
(fr)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Récepteur a de il-il-17 requis pour biologie il-17c
|
US8579924B2
(en)
|
2011-07-26 |
2013-11-12 |
Covidien Lp |
Implantable devices including a mesh and a pivotable film
|
WO2013017656A1
(fr)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonistes de ribonucléases pour traiter l'obésité
|
WO2013025939A2
(fr)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Composés et méthodes de traitement du cancer par l'inhibition du récepteur de l'urokinase
|
WO2013024144A1
(fr)
|
2011-08-16 |
2013-02-21 |
Evotec (München) Gmbh |
Marqueurs de sensibilité à un inhibiteur de kinase de la famille src
|
EP2744828A4
(fr)
|
2011-08-16 |
2014-12-31 |
Univ Emory |
Agents spécifiques de liaison à jaml, anticorps, et leurs utilisations associées
|
ES2664224T3
(es)
|
2011-08-19 |
2018-04-18 |
Children's Medical Center Corporation |
Proteína de unión a VEGF para el bloqueo de la angiogénesis
|
US9782957B2
(en)
|
2011-08-24 |
2017-10-10 |
Covidien Lp |
Medical device films
|
US20140213512A1
(en)
|
2011-08-31 |
2014-07-31 |
Amgen Inc. |
Method of Treating or Ameliorating Type 1 Diabetes Using FGF21
|
WO2013039916A1
(fr)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions et méthodes de traitement et de détection améliorée de tumeurs non pituitaires
|
ES2806146T3
(es)
|
2011-09-22 |
2021-02-16 |
Amgen Inc |
Proteínas de unión al antígeno CD27L
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
UY34346A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de fusión para tratar trastornos metabólicos
|
CN110655578A
(zh)
|
2011-09-30 |
2020-01-07 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
DE102011114864A1
(de)
|
2011-10-05 |
2013-04-11 |
Acino Ag |
Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
|
WO2013053076A1
(fr)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions et procédés pour le traitement de l'insuffisance cardiaque
|
WO2013056255A1
(fr)
|
2011-10-14 |
2013-04-18 |
The Board Of Trustees Of The University Of Illinois |
Procédés et compositions pour inhiber la prolifération de cellules tumorales
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
US9499464B2
(en)
|
2011-10-19 |
2016-11-22 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
US8932621B2
(en)
|
2011-10-25 |
2015-01-13 |
Covidien Lp |
Implantable film/mesh composite
|
US9005308B2
(en)
|
2011-10-25 |
2015-04-14 |
Covidien Lp |
Implantable film/mesh composite for passage of tissue therebetween
|
US9179994B2
(en)
|
2011-10-25 |
2015-11-10 |
Covidien Lp |
Implantable film/mesh composite
|
MX2014005957A
(es)
|
2011-11-16 |
2015-02-04 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico.
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
AU2012346214B2
(en)
|
2011-11-30 |
2017-09-14 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
CN104185420B
(zh)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
|
JP6322142B2
(ja)
|
2011-12-01 |
2018-05-09 |
ビカム ファーマスーティカルス,インコーポレイテッド |
オプシン結合性リガンド、組成物、及び使用方法
|
US20150284471A1
(en)
|
2011-12-08 |
2015-10-08 |
Amgen Inc |
Human LCAT Antigen Binding Proteins and Their Use in Therapy
|
WO2013083810A1
(fr)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification de non-répondeurs aux inhibiteurs de her2
|
CN104144946A
(zh)
|
2011-12-19 |
2014-11-12 |
爱克索马美国有限责任公司 |
治疗痤疮的方法
|
EA201491231A8
(ru)
|
2011-12-19 |
2015-01-30 |
Амген Инк. |
Варианты полипептидов рецептора активина и их применение
|
US10736935B2
(en)
|
2011-12-22 |
2020-08-11 |
Children's Medical Center Corporation |
Saposin-A derived peptides and uses thereof
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
WO2013106489A1
(fr)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Anticorps humanisés à cdr3 ultralongues
|
US9512212B2
(en)
|
2012-01-11 |
2016-12-06 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
CN104204218A
(zh)
|
2012-01-26 |
2014-12-10 |
安姆根有限公司 |
生长分化因子15 (gdf-15)多肽
|
EP2626066A1
(fr)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Polythérapie comprenant des inhibiteurs VEGFR-2 sélectifs et inhibiteurs MEK
|
US9879012B2
(en)
|
2012-03-29 |
2018-01-30 |
Regents Of The University Of Colorado, A Body Corporate |
Click nucleic acids
|
US10206769B2
(en)
|
2012-03-30 |
2019-02-19 |
Covidien Lp |
Implantable devices including a film providing folding characteristics
|
US8753643B1
(en)
|
2012-04-11 |
2014-06-17 |
Life-Science Innovations, Llc |
Spray dried compositions and methods of use
|
RU2014145682A
(ru)
|
2012-04-14 |
2016-06-10 |
Интра-Селлулар Терапиз, Инк |
Органические соединения
|
AU2013253581B2
(en)
|
2012-04-23 |
2019-05-16 |
Genefrontier Corporation |
Anti-human CD69 antibody, and use thereof for medical purposes
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
NZ702178A
(en)
|
2012-05-14 |
2017-01-27 |
Biogen Ma Inc |
Lingo-2 antagonists for treatment of conditions involving motor neurons
|
JO3623B1
(ar)
|
2012-05-18 |
2020-08-27 |
Amgen Inc |
البروتينات المرتبطة بمولد المستضاد st2
|
WO2013177187A2
(fr)
|
2012-05-22 |
2013-11-28 |
Massachusetts Institute Of Technology |
Traitement de tumeur synergique avec du pk il-2 étendu et des agents thérapeutiques
|
FR2992662B1
(fr)
|
2012-06-28 |
2014-08-08 |
Sofradim Production |
Tricot avec picots
|
FR2992547B1
(fr)
|
2012-06-29 |
2015-04-24 |
Sofradim Production |
Prothese pour hernie
|
EP2866821B1
(fr)
|
2012-07-02 |
2018-11-14 |
Medizinische Universität Wien |
Produit de séparation du complément c4d pour le traitement d'affections inflammatoires
|
EP2687225A1
(fr)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
Protéine HIP/PAP et ses dérivés pour une utilisation dans le traitement du cancer
|
CN104797574B
(zh)
|
2012-07-25 |
2019-11-22 |
原生质生物科学股份有限公司 |
Lfa-1抑制剂及其多晶型物
|
DE102013011399A1
(de)
|
2012-07-31 |
2014-02-06 |
Amw Gmbh |
Implantat mit Risperidon
|
EP2695950A1
(fr)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Marqueurs pour la réactivité à un inhibiteur du récepteur du facteur de croissance des fibroblastes
|
WO2014031649A1
(fr)
|
2012-08-21 |
2014-02-27 |
Genesys Research Institute |
Compositions et méthodes de traitement ou de prévention de la cardiotoxicité induite par l'anthracycline
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
SG11201502941VA
(en)
|
2012-10-17 |
2015-05-28 |
Vascular Biogenics Ltd |
Treatment methods using adenovirus
|
CA2890862C
(fr)
|
2012-11-09 |
2021-10-12 |
Genefrontier Corporation |
Anticorps anti-adam28 pour traiter le cancer
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
CN104813168B
(zh)
|
2012-11-30 |
2017-10-20 |
霍夫曼-拉罗奇有限公司 |
需要pd‑l1抑制剂综合疗法的患者的鉴定
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
EP2934588A4
(fr)
|
2012-12-20 |
2016-09-28 |
Medimmune Llc |
Formulation d'anticorps liquide ayant des propriétés d'agrégation améliorées
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
AU2014212014A1
(en)
|
2013-02-01 |
2015-08-27 |
Amgen Inc. |
Administration of an anti-activin-A compound to a subject
|
CA2900008A1
(fr)
|
2013-02-07 |
2014-08-14 |
Children's Medical Center Corporation |
Antigenes de proteine qui conferent une protection contre une colonisation et/ou une maladie pneumococcique
|
EP2958577A2
(fr)
|
2013-02-25 |
2015-12-30 |
Synergy Pharmaceuticals Inc. |
Agonistes du recepteur de la guanylate cyclase pour l'utilisation dans l'irrigation du colon
|
US20140308352A1
(en)
|
2013-03-11 |
2014-10-16 |
Zogenix Inc. |
Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
|
BR112015022023B1
(pt)
|
2013-03-11 |
2022-12-06 |
Durect Corporation |
Composição de liberação controlada injetável compreendendo transportador líquido de alta viscosidade
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
AU2014244444A1
(en)
|
2013-03-14 |
2015-09-24 |
Amgen Inc. |
CHRDL-1 antigen binding proteins and methods of treatment
|
AR095596A1
(es)
|
2013-03-15 |
2015-10-28 |
Amgen Res (Munich) Gmbh |
Moléculas de unión de cadena única comprendiendo n-terminal abp
|
EP2968480B1
(fr)
|
2013-03-15 |
2020-10-14 |
Amgen Inc. |
Traitement de troubles métaboliques au moyen de polypeptides de pla2g12a et de polypeptides mutants de pla2g12a
|
CN105143267B
(zh)
|
2013-03-15 |
2020-06-26 |
美国安进公司 |
人pac1抗体
|
WO2014151206A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
WO2014144553A1
(fr)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Protéines de liaison à la protéine sfrp5 (secreted frizzled-related protein 5) et méthodes de traitement
|
JP6469644B2
(ja)
|
2013-03-15 |
2019-02-13 |
アムジエン・インコーポレーテツド |
抗ccr7抗原結合タンパク質に関係する方法および組成物
|
CA2905435A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions utiles pour le traitement de troubles gastro-intestinaux
|
EP2968320B1
(fr)
|
2013-03-15 |
2020-11-11 |
Intra-Cellular Therapies, Inc. |
Composés organiques
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
AU2014233453A1
(en)
|
2013-03-15 |
2015-10-01 |
Durect Corporation |
Compositions with a rheological modifier to reduce dissolution variability
|
WO2014144817A2
(fr)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
|
JP6151848B2
(ja)
*
|
2013-04-18 |
2017-06-21 |
シャンドン ルイ ファーマシューティカル カンパニー リミテッド |
ゴセレリン徐放性マイクロスフェア医薬組成物
|
EP2999797B1
(fr)
|
2013-05-21 |
2018-07-04 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoformes spécifiques de gata6 et nkx2-1 en tant que nouveaux marqueurs pour les approches de diagnostic et de thérapie du cancer et en tant que cibles pour la thérapie anticancéreuse
|
BR112015029293A2
(pt)
|
2013-05-22 |
2018-04-24 |
Zensun Shanghai Science & Tech Ltd |
método e kit para prevenir, tratar ou retardar uma doença ou distúrbio cardiovascular em um mamífero
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
WO2014194274A2
(fr)
|
2013-05-30 |
2014-12-04 |
Biogen Idec Ma Inc. |
Protéines de liaison à l'antigène du récepteur de l'oncostatine m
|
EP2810648A1
(fr)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Interaction domaine-domaine de ciblage pour l'identification des modulateurs de kinase
|
EP3009518B1
(fr)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Procédé permettant de prédire le pronostic post-thérapie d'un patient atteint de sclérose en plaques à périodes progressives et rémittentes (spppr) et procédé permettant de déterminer l'applicabilité d'une nouvelle thérapie
|
WO2014197938A1
(fr)
|
2013-06-13 |
2014-12-18 |
Antisense Therapeutics Ltd |
Polythérapie
|
US10154971B2
(en)
|
2013-06-17 |
2018-12-18 |
Adamas Pharma, Llc |
Methods of administering amantadine
|
EP2835135A3
(fr)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Moyens et procédés pour traiter une infection par Pseudomonas
|
AU2013396206B2
(en)
|
2013-06-28 |
2019-11-14 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
WO2015017146A2
(fr)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Anticorps à régions de détermination de complémentarité ultralongues
|
MA38873B1
(fr)
|
2013-07-31 |
2018-11-30 |
Amgen Inc |
Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
|
WO2015022326A1
(fr)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides en tant qu'agents actifs pour le traitement d'un dysfonctionnement du greffon primaire
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
AU2014318017B2
(en)
|
2013-09-05 |
2020-02-06 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
EP3043790B1
(fr)
|
2013-09-11 |
2021-05-26 |
The Administrators of the Tulane Educational Fund |
Nouveaux amides anthraniliques et utilisation de ces derniers
|
JP6822839B2
(ja)
|
2013-09-13 |
2021-01-27 |
ザ・スクリップス・リサーチ・インスティテュート |
修飾された治療剤、及びその組成物
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向cd33及cd3之雙特異性化合物的組合
|
JP6745220B2
(ja)
|
2013-09-16 |
2020-08-26 |
ツェーエムエム−フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー |
骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン
|
GB201316738D0
(en)
|
2013-09-20 |
2013-11-06 |
Rainbow Medical Engineering Ltd |
Implantable Medical Devices
|
US20160229922A1
(en)
|
2013-09-20 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
ES2724300T3
(es)
|
2013-09-25 |
2019-09-10 |
Univ Cornell |
Compuestos para inducir inmunidad antitumoral y métodos de lo mismo
|
WO2015051304A1
(fr)
|
2013-10-04 |
2015-04-09 |
Aptose Biosciences Inc. |
Compositions, biomarqueurs et leur utilisation dans le traitement du cancer
|
MY176976A
(en)
|
2013-10-10 |
2020-08-28 |
Bausch Health Ireland Ltd |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
KR102339240B1
(ko)
|
2013-10-15 |
2021-12-15 |
더 스크립스 리서치 인스티튜트 |
펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
|
ES2741308T3
(es)
|
2013-10-15 |
2020-02-10 |
Scripps Research Inst |
Interruptores de células T con receptores de antígenos quiméricos y usos de los mismos
|
WO2015056808A1
(fr)
|
2013-10-15 |
2015-04-23 |
Genefrontier Corporation |
Anticorps humain contre les espèces adamts de type agrécanase pour des agents thérapeutiques contre des maladies associées à l'agrécanase
|
WO2015057908A1
(fr)
|
2013-10-18 |
2015-04-23 |
Novartis Ag |
Méthodes de traitement du diabete et de troubles associés
|
WO2015061856A1
(fr)
|
2013-10-30 |
2015-05-07 |
University Of Western Australia |
Peptides neuroprotecteurs
|
WO2015066550A1
(fr)
|
2013-10-31 |
2015-05-07 |
Resolve Therapeutics, Llc |
Fusions nucléase-albumine à visée thérapeutique et procédés associés
|
GB201319374D0
(en)
|
2013-11-01 |
2013-12-18 |
Univ Nottingham |
Glycans as functional cancer targets abd antibodies thereto
|
WO2015085004A1
(fr)
|
2013-12-03 |
2015-06-11 |
Intra-Cellular Therapies, Inc. |
Nouveaux procédés
|
EP4212180A1
(fr)
|
2013-12-18 |
2023-07-19 |
The Scripps Research Institute |
Agents thérapeutiques modifiés, conjugués lipidiques peptidiques agrafés et compositions associées
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
WO2015110930A1
(fr)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Protéines de récepteur d'interleukine 21 modifiées
|
US10189908B2
(en)
|
2014-02-05 |
2019-01-29 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
|
EP3104873B1
(fr)
|
2014-02-13 |
2019-09-04 |
Technische Universität München |
Fgf-8 pour son utilisation dans le traitement des maladies ou des troubles de l'homéostasie énergétique
|
CA2939626C
(fr)
|
2014-02-20 |
2023-01-17 |
Allergan, Inc. |
Anticorps anti-composant c5 de du systeme de complement
|
US9796776B2
(en)
|
2014-02-27 |
2017-10-24 |
Allergan, Inc. |
Complement factor Bb antibodies
|
CN106458856A
(zh)
|
2014-03-07 |
2017-02-22 |
约翰霍普金斯大学 |
组蛋白赖氨酸特异性的脱甲基酶(lsd1)和组蛋白脱乙酰基酶(hdac)的抑制剂
|
CA2942078C
(fr)
|
2014-03-14 |
2023-03-14 |
The University Of North Carolina At Chapel Hill |
Petites molecules pour inhiber la fertilite male
|
EP3125892A4
(fr)
|
2014-04-04 |
2017-12-27 |
Intra-Cellular Therapies, Inc. |
Composés organiques
|
KR20220054908A
(ko)
|
2014-04-04 |
2022-05-03 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
유기 화합물
|
US10507227B2
(en)
|
2014-04-15 |
2019-12-17 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
EP3131532A1
(fr)
|
2014-04-16 |
2017-02-22 |
Veyx-Pharma GmbH |
Composition pharmaceutique vétérinaire et utilisation de ladite composition pharmaceutique vétérinaire
|
US20170073690A1
(en)
|
2014-05-15 |
2017-03-16 |
CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH |
Antagonists of slc38a9 and their use in therapy
|
US20170119851A1
(en)
|
2014-05-19 |
2017-05-04 |
Novartis Ag |
Methods of treating anorexia
|
WO2015184260A2
(fr)
|
2014-05-30 |
2015-12-03 |
The Johns Hopkins University |
Méthodes de traitement de troubles mendélien de la machinerie épigénétiques
|
KR101753553B1
(ko)
|
2014-06-03 |
2017-07-03 |
엑스바이오테크, 인크. |
스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
|
AU2015275128C1
(en)
|
2014-06-09 |
2020-02-13 |
Kyowa Kirin Co., Ltd. |
The effective and efficient control of serum phosphate for optimal bone formation
|
WO2015191554A1
(fr)
|
2014-06-09 |
2015-12-17 |
Intra-Cellular Therapies, Inc. |
Composés et leurs procédés d'utilisation pour traiter la schizophrénie
|
CN107074931A
(zh)
|
2014-06-13 |
2017-08-18 |
圣塔玛丽亚生物疗法公司 |
经配制的受体多肽和相关方法
|
TWI831106B
(zh)
|
2014-06-20 |
2024-02-01 |
日商中外製藥股份有限公司 |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
WO2016007919A2
(fr)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Fragments d'anticorps pour détecter un cancer et méthodes d'utilisation
|
EP2977758A1
(fr)
|
2014-07-24 |
2016-01-27 |
Université De Nice Sophia Antipolis |
Procédés et kits pour surveiller la néphropathie membraneuse
|
AU2015294834B2
(en)
|
2014-07-31 |
2021-04-29 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
DK3180018T3
(da)
|
2014-08-12 |
2019-10-28 |
Massachusetts Inst Technology |
Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
|
WO2016025645A1
(fr)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Traitement tumoral synergique avec l'il-2, un anticorps thérapeutique, et un bloqueur de point de contrôle immunitaire
|
CA2958879A1
(fr)
|
2014-08-22 |
2016-02-25 |
Auckland Uniservices Limited |
Modulateurs de canaux
|
AU2015307186A1
(en)
|
2014-08-27 |
2017-04-13 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
WO2016040767A2
(fr)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Anticorps et épitopes chrdl-1
|
WO2016064969A1
(fr)
|
2014-10-21 |
2016-04-28 |
Sciclone Pharmaceuticals, Inc. |
Traitement du cancer au moyen de stimulateurs immunitaires
|
CN114805533A
(zh)
|
2014-10-24 |
2022-07-29 |
百时美施贵宝公司 |
修饰的fgf-21多肽及其用途
|
WO2016069889A1
(fr)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Hybrides nucléase-transferrine à visée thérapeutique et procédés associés
|
WO2016079321A1
(fr)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonistes de setdb2 pour leur utilisation dans la thérapie de maladies infectieuses
|
EP3085709B1
(fr)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Anticorps anti-rankl humain humanisé, composition pharmaceutique et son utilisation
|
AU2016205197B2
(en)
|
2015-01-08 |
2021-10-21 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
WO2016123143A1
(fr)
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13rα2 spécifique au cancer
|
US9744239B2
(en)
|
2015-01-30 |
2017-08-29 |
Par Pharmaceutical, Inc. |
Vasopressin formulations for use in treatment of hypotension
|
RU2722832C2
(ru)
|
2015-02-23 |
2020-06-04 |
Сигалл Терапьютикс Сас |
Неприродные семафорины класса 3 и их медицинское применение
|
WO2016154621A1
(fr)
|
2015-03-26 |
2016-09-29 |
The California Institute For Biomedical Research |
Récepteurs chimériques non-scfv commutables, commutateurs, et leurs utilisations
|
WO2016164937A2
(fr)
|
2015-04-10 |
2016-10-13 |
Amgen Inc. |
Mutéines de l'interleukine-2 pour l'expansion de lymphocytes t régulateurs
|
UA126270C2
(uk)
|
2015-04-10 |
2022-09-14 |
Емджен Інк. |
Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
|
EP3283113A4
(fr)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Commutateurs de lymphocytes t à récepteurs d'antigènes chimères à base de pne optimisés et leurs utilisations
|
EP4276116A3
(fr)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Constructions d'anticorps bispécifiques pour cdh3 et cd3
|
US20180146703A1
(en)
*
|
2015-05-15 |
2018-05-31 |
The Johns Hopkins University |
Novel fluoride prenatal dietary supplement
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
WO2016205488A1
(fr)
|
2015-06-17 |
2016-12-22 |
The California Institute For Biomedical Research |
Agents thérapeutiques modifiés et compositions associées
|
EP3319613B1
(fr)
|
2015-07-07 |
2023-02-22 |
The Research Foundation for The State University of New York |
Utilisation d'amines carboxyboranes pour l'administration thérapeutique de monoxyde de carbone et en tant que système d'administration de médicament général en présence d'espèces réactives de l'oxygène
|
ES2546566B2
(es)
|
2015-07-23 |
2016-09-14 |
Universidade De Santiago De Compostela |
Sistema para la administración de sustancias biológicamente activas preparado por técnicas de espumado empleando gases comprimidos o fluidos supercríticos
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
WO2017023774A1
(fr)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Promédicaments d'analogues de glutamine
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
EP3328374A4
(fr)
|
2015-07-31 |
2019-03-13 |
The Johns Hopkins University |
Antagonistes de la glutamine pour le traitement de déficits cognitifs
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
WO2017023793A2
(fr)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Procédés pour le cancer et l'immunothérapie au moyen des analogues de glutamine, comprenant le désoxynivalénol (don)
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
MA42985A
(fr)
|
2015-10-01 |
2018-08-22 |
Amgen Inc |
Traitement de troubles liés à l'acide biliaire
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
KR20180077271A
(ko)
|
2015-11-03 |
2018-07-06 |
암브룩스, 인코포레이티드 |
항-cd3-폴레이트 컨쥬게이트 및 이의 용도
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
WO2017086367A1
(fr)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
Polythérapie utilisant une molécule de liaison à l'antigène à rôle de redirection des cellules t, ciblant des cellules immunosupressives
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
DK3391902T3
(da)
|
2015-12-18 |
2023-11-20 |
Talengen Int Ltd |
Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
|
NZ743474A
(en)
|
2015-12-23 |
2023-03-31 |
Amgen Inc |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
|
EP3395835B1
(fr)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Anticorps présentant une activité accrue et son procédé de modification
|
WO2017123634A1
(fr)
|
2016-01-11 |
2017-07-20 |
Synergy Pharmaceuticals, Inc. |
Formulations et méthodes pour traiter la rectocolite hémorragique
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
IL296884B2
(en)
|
2016-01-26 |
2024-05-01 |
Intra Cellular Therapies Inc |
Condensed heterocyclic converted gamma carbonyls for use in the treatment of central nervous system disorders
|
CR20180418A
(es)
|
2016-02-03 |
2019-01-15 |
Amgen Res Munich Gmbh |
Contructos de anticuerpo biespecpificos para psma y cd3 que se ligan a células t
|
MD3411402T2
(ro)
|
2016-02-03 |
2022-05-31 |
Amgen Res Munich Gmbh |
Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
US10098909B2
(en)
|
2016-02-05 |
2018-10-16 |
University Of South Florida |
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
|
CN110092830B
(zh)
|
2016-02-10 |
2023-07-04 |
新泽西鲁特格斯州立大学 |
用于诊断和治疗结核分枝杆菌感染的抗lam和抗pim6/lam单克隆抗体
|
EP3216458A1
(fr)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Facteur de croissance endothéliale vasculaire (vegf-a)modifié et son utilisation médicale
|
RU2746754C2
(ru)
|
2016-03-14 |
2021-04-20 |
Чугаи Сейяку Кабусики Кайся |
Индуцирующее повреждение клеток терапевтическое лекарственное средство, предназначенное для противораковой терапии
|
CN113754661A
(zh)
|
2016-03-25 |
2021-12-07 |
细胞内治疗公司 |
有机化合物
|
EP3436083A4
(fr)
|
2016-03-28 |
2019-11-27 |
Intra-Cellular Therapies, Inc. |
Nouvelles compositions et méthodes
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
AU2017290389A1
(en)
|
2016-07-01 |
2019-02-14 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
US10300145B2
(en)
|
2016-07-15 |
2019-05-28 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
AU2017310412A1
(en)
|
2016-08-08 |
2019-02-21 |
Amgen Inc. |
Method of improving connective tissue attachment using anti-sclerostin antibodies
|
WO2018044970A1
(fr)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Anticorps monoclonaux humains dirigés contre l'enveloppe du rétrovirus endogène humain k (herv-k) et leurs utilisations
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
MX2019000735A
(es)
|
2016-09-16 |
2019-12-02 |
Res Triangle Inst |
Antagonistas opioides kappa de tetrahidroisoquinolina.
|
WO2018071233A1
(fr)
|
2016-10-12 |
2018-04-19 |
Intra-Cellular Therapies, Inc. |
Dispersions solides amorphes
|
KR20230172612A
(ko)
|
2016-10-19 |
2023-12-22 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
CA3047171A1
(fr)
|
2016-12-15 |
2018-06-21 |
Talengen International Limited |
Procede de prevention et de traitement d'une lesion de tissu renal pathologique
|
EP3556381A4
(fr)
|
2016-12-15 |
2020-09-23 |
Talengen International Limited |
Médicament pour la prévention et le traitement de l'ostéoporose et ses utilisations
|
EP3556384B1
(fr)
|
2016-12-15 |
2024-04-10 |
Talengen International Limited |
Plasminogène pour le traitement du diabète
|
TW201829448A
(zh)
|
2016-12-15 |
2018-08-16 |
大陸商深圳瑞健生命科學硏究院有限公司 |
纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途
|
CA3046666A1
(fr)
|
2016-12-15 |
2018-06-21 |
Talengen International Limited |
Methode de prevention et de traitement de fibrose de tissu et d'organe
|
US11389515B2
(en)
|
2016-12-15 |
2022-07-19 |
Talengen International Limited |
Method for mitigating heart disease
|
TWI684459B
(zh)
|
2016-12-15 |
2020-02-11 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種治療動脈粥樣硬化及其併發症的方法
|
WO2018126143A1
(fr)
|
2016-12-29 |
2018-07-05 |
Intra-Cellular Therapies, Inc. |
Composés organiques
|
US10961245B2
(en)
|
2016-12-29 |
2021-03-30 |
Intra-Cellular Therapies, Inc. |
Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
|
EP3567054A4
(fr)
|
2017-01-06 |
2021-03-10 |
ABL Bio Inc. |
Anticorps anti-alpha-syn et son utilisation
|
WO2018129470A1
(fr)
|
2017-01-09 |
2018-07-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inversion de signalisation hedgehog déficiente restaurant la régénération squelettique déficiente
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
EP3568143B1
(fr)
|
2017-01-11 |
2023-12-13 |
Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung |
Vésicules extracellulaires dérivées de cellules souches mésenchymateuses et leur utilisation médicale
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
TW201837051A
(zh)
|
2017-02-08 |
2018-10-16 |
美商必治妥美雅史谷比公司 |
包含藥物動力學增強劑之經修飾之鬆弛素(relaxin)多肽及其用途
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
WO2018160791A1
(fr)
|
2017-03-03 |
2018-09-07 |
Massachusetts Institute Of Technology |
Constructions antimicrobiennes et leurs utilisations
|
US10421968B2
(en)
|
2017-03-15 |
2019-09-24 |
Versitech Limited |
Amphiphilic dendrimers complexed with siRNA for treatment of cancer
|
BR112019019875A2
(pt)
|
2017-03-24 |
2020-04-22 |
Intra Cellular Therapies Inc |
novas composições e métodos
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
RU2019136495A
(ru)
|
2017-05-04 |
2021-06-04 |
Хельсингин Илиописто |
C-концевые фрагменты cdnf и маnf, фармацевтические композиции, содержащие указанные фрагменты, и применения указанных фрагментов и композиций
|
CN110913904A
(zh)
|
2017-05-05 |
2020-03-24 |
美国安进公司 |
用于改善的储存和施用的包含双特异性抗体构建体的药物组合物
|
AU2018265584B2
(en)
|
2017-05-12 |
2023-09-28 |
Ludwig-Maximilians-Universität München |
Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
WO2018233604A1
(fr)
|
2017-06-19 |
2018-12-27 |
泰伦基国际有限公司 |
Procédé de régulation et contrôle de glp-1/glp-1r et médicament associé
|
WO2018236904A1
(fr)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations
|
AU2018288854A1
(en)
|
2017-06-20 |
2019-11-21 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
CA3070089A1
(fr)
|
2017-07-19 |
2019-01-24 |
Auckland Uniservices Limited |
Modulation de cytokine
|
EP3658144B1
(fr)
|
2017-07-26 |
2022-01-26 |
Intra-Cellular Therapies, Inc. |
Composés pyridopyrroloquinoxalines, leurs compositions et utilisations en thérapie
|
US11376249B2
(en)
|
2017-07-26 |
2022-07-05 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
EP3665202A1
(fr)
|
2017-08-09 |
2020-06-17 |
Massachusetts Institute Of Technology |
Conjugués peptidiques de liaison à l'albumine et leurs procédés
|
EP3684811A2
(fr)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Agents de liaison à spécificité multiple de chimiokines cxc et leurs utilisations
|
AU2018321359B2
(en)
|
2017-08-22 |
2023-11-30 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
EP3684408A1
(fr)
|
2017-09-19 |
2020-07-29 |
Massachusetts Institute of Technology |
Compositions pour la thérapie par lymphocytes t à récepteur antigénique chimérique et leurs utilisations
|
MX2020003549A
(es)
|
2017-10-04 |
2020-08-03 |
Amgen Inc |
Fusiones de transtiretina e inmunoglobulina.
|
KR20200074160A
(ko)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
WO2019089365A1
(fr)
|
2017-10-30 |
2019-05-09 |
Enterin Laboratories, Inc. |
Nouvelles formes solides de squalamine et procédés pour les produire
|
WO2019089753A2
(fr)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Anticorps cd137 et antagonistes pd-1 et leurs utilisations
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
US20210163592A1
(en)
|
2017-12-11 |
2021-06-03 |
Amgen Inc |
Continuous manufacturing process for bispecific antibody products
|
CN111465408B
(zh)
|
2017-12-15 |
2023-07-04 |
泰伦基国际有限公司 |
一种预防或治疗骨关节炎的方法和药物
|
KR20200101954A
(ko)
|
2017-12-19 |
2020-08-28 |
메사추세츠 인스티튜트 오브 테크놀로지 |
항원-아주반트 커플링 시약 및 사용 방법
|
US11667713B2
(en)
|
2017-12-28 |
2023-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
JP7458790B2
(ja)
|
2018-01-31 |
2024-04-01 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
JP2021512917A
(ja)
|
2018-02-09 |
2021-05-20 |
ガルデルマ ホールディング エスエー |
中等度から重度の掻破痕を有するアトピー性皮膚炎の治療におけるネモリズマブ
|
KR102411489B1
(ko)
|
2018-03-14 |
2022-06-23 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
WO2019178484A1
(fr)
|
2018-03-16 |
2019-09-19 |
Intra-Cellular Therapies, Inc. |
Nouveaux procédés
|
CA3093740A1
(fr)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anticorps anti-il-27 et leurs utilisations
|
CN112040940A
(zh)
|
2018-03-23 |
2020-12-04 |
细胞内治疗公司 |
有机化合物
|
SG11202009341TA
(en)
|
2018-03-29 |
2020-10-29 |
Helsingin Yliopisto |
C-terminal cdnf fragments, pharmaceutical compositions comprising same and uses thereof
|
BR112020020080A2
(pt)
|
2018-03-30 |
2021-01-05 |
Amgen Inc |
Variantes de anticorpos c-terminais
|
PE20201350A1
(es)
|
2018-04-09 |
2020-11-30 |
Amgen Inc |
Proteinas de fusion del factor de diferenciacion de crecimiento 15
|
WO2019200357A1
(fr)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarqueur pour agents thérapeutiques ciblant cd47 et leurs utilisations
|
CN112105733A
(zh)
|
2018-04-19 |
2020-12-18 |
查美特制药公司 |
合成rig-i样受体激动剂
|
WO2019207051A1
(fr)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Utilisation médicale de combinaisons de sémaphorines 3 et d'antimétabolites non naturels
|
EP3797120A1
(fr)
|
2018-05-21 |
2021-03-31 |
Compass Therapeutics LLC |
Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk
|
WO2019226658A1
(fr)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
|
WO2019225787A1
(fr)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
Anticorps anti-b7-h3 et son utilisation
|
KR20210031455A
(ko)
|
2018-06-11 |
2021-03-19 |
인트라-셀룰라 써래피스, 인코퍼레이티드. |
치환된 헤테로환 융합 감마-카르볼린 합성
|
WO2020011938A1
(fr)
|
2018-07-11 |
2020-01-16 |
Medizinische Universität Wien |
Glucocorticoïdes pour le traitement topique de la gastrite auto-immune
|
WO2020018715A1
(fr)
|
2018-07-17 |
2020-01-23 |
Massachusetts Institute Of Technology |
Protéines de fusion à base d'échafaudage d'immunoglobuline multimère soluble et leurs utilisations
|
WO2020033926A2
(fr)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Anticorps qui se lient à cd277 et leurs utilisations
|
WO2020033923A1
(fr)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Agents de liaison à l'antigène qui se lient à cd277 et leurs utilisations
|
WO2020033925A2
(fr)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Anticorps qui se lient à cd277 et leurs utilisations
|
MX2021002301A
(es)
|
2018-08-28 |
2021-04-28 |
Ambrx Inc |
Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
|
US10695345B2
(en)
|
2018-08-31 |
2020-06-30 |
Intra-Cellular Therapies, Inc. |
Pharmaceutical capsule compositions comprising lumateperone mono-tosylate
|
WO2020047407A1
(fr)
|
2018-08-31 |
2020-03-05 |
Intra-Cellular Therapies, Inc. |
Nouvelles méthodes
|
PT3849614T
(pt)
|
2018-09-11 |
2024-02-28 |
Ambrx Inc |
Conjugados de polipeptídeos de interleucina-2 e suas utilizações
|
WO2020053808A1
(fr)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Procédé de diagnostic de troubles vasorégulateurs
|
SG11202100935TA
(en)
|
2018-09-28 |
2021-02-25 |
Massachusetts Inst Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
CA3114802A1
(fr)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Traitement en aval de constructions d'anticorps bispecifiques
|
JP2022512746A
(ja)
|
2018-10-19 |
2022-02-07 |
アンブルックス,インコーポレイテッド |
インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用
|
US20220089786A1
(en)
|
2019-01-04 |
2022-03-24 |
Resolve Therapeutics, Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
US11235032B2
(en)
|
2019-01-23 |
2022-02-01 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
US11236157B2
(en)
|
2019-01-28 |
2022-02-01 |
Galderma Holding SA |
Treatment of skin lesions and pruritus in prurigo nodularis patients
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
US20220226488A1
(en)
|
2019-02-12 |
2022-07-21 |
Ambrx, Inc. |
Compositions containing, methods and uses of antibody-tlr agonist conjugates
|
JP2022525781A
(ja)
|
2019-03-20 |
2022-05-19 |
マサチューセッツ インスティテュート オブ テクノロジー |
免疫細胞療法における両親媒性物質の使用およびそのための組成物
|
JPWO2020202839A1
(fr)
|
2019-03-29 |
2020-10-08 |
|
|
CA3135694A1
(fr)
|
2019-04-17 |
2020-10-22 |
Hiroshima University |
Agent therapeutique pour cancer urologique caracterise en ce qu'il est administre avec un inhibiteur de il-6 et un inhibiteur de ccr2 en combinaison
|
EP3967322A4
(fr)
|
2019-05-10 |
2022-06-08 |
Talengen International Limited |
Procédé et médicament pour le traitement de la sclérose latérale amyotrophique
|
CN113924119A
(zh)
|
2019-05-31 |
2022-01-11 |
国立大学法人大阪大学 |
新型的消化器官癌治疗剂及其筛选方法
|
MX2021014433A
(es)
|
2019-06-05 |
2022-03-11 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a sitio de escision de anticuerpo.
|
KR102486064B1
(ko)
|
2019-06-10 |
2023-01-06 |
추가이 세이야쿠 가부시키가이샤 |
사이토카인 저해제와 조합하여 사용하기 위한 항t세포 항원 결합 분자
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
WO2020263399A1
(fr)
|
2019-06-26 |
2020-12-30 |
Massachusetts Institute Of Technology |
Complexes protéine de fusion-hydroxyde métallique immunomodulateurs et leurs procédés
|
EP3993798A4
(fr)
|
2019-07-07 |
2023-04-26 |
Intra-Cellular Therapies, Inc. |
Nouveaux procédés
|
JP2022540089A
(ja)
|
2019-07-08 |
2022-09-14 |
アムジエン・インコーポレーテツド |
多特異性トランスサイレチン免疫グロブリン融合物
|
SG11202112307YA
(en)
|
2019-07-10 |
2021-12-30 |
Chugai Pharmaceutical Co Ltd |
Claudin-6 binding molecules and uses thereof
|
CA3148591A1
(fr)
|
2019-07-26 |
2021-02-04 |
Amgen Inc. |
Proteines de liaison a un antigene anti-il13
|
GB201910900D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
GB201910899D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Binding members
|
EP4013776A1
(fr)
|
2019-08-13 |
2022-06-22 |
Amgen Inc. |
Mutéines de l'interleukine-2 pour l'expansion de lymphocytes t régulateurs
|
GB201912657D0
(en)
|
2019-09-03 |
2019-10-16 |
Scancell Ltd |
Binding members
|
GB201912882D0
(en)
|
2019-09-06 |
2019-10-23 |
Scancell Ltd |
Ssea-4 binding members
|
KR20220062500A
(ko)
|
2019-09-16 |
2022-05-17 |
서피스 온콜로지, 인크. |
항-cd39 항체 조성물 및 방법
|
AU2020353672A1
(en)
|
2019-09-25 |
2022-03-31 |
Surface Oncology, LLC |
Anti-IL-27 antibodies and uses thereof
|
TWI745114B
(zh)
|
2019-10-11 |
2021-11-01 |
日商中外製藥股份有限公司 |
用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
|
CN115279905A
(zh)
|
2019-10-23 |
2022-11-01 |
里珍纳龙药品有限公司 |
合成rig-i样受体激动剂
|
WO2021080682A1
(fr)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Anticorps monoclonaux qui se lient au cd161 humain et leurs utilisations
|
AU2020371784A1
(en)
|
2019-10-24 |
2022-06-02 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
EP4058485A1
(fr)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Procédé de réduction de la formation d'agrégats dans le traitement en aval de molécules de liaison à l'antigène bispécifiques
|
JP2023502794A
(ja)
|
2019-11-19 |
2023-01-25 |
モダグ ゲーエムベーハー |
α-シヌクレインの凝集に関連する疾患の診断、治療および予防のための新規な化合物
|
EP4072554A4
(fr)
|
2019-12-11 |
2023-12-20 |
Intra-Cellular Therapies, Inc. |
Composé organique
|
JP2023507115A
(ja)
|
2019-12-17 |
2023-02-21 |
アムジエン・インコーポレーテツド |
治療における使用のためのデュアルインターロイキン-2/tnf受容体アゴニスト
|
EP3838345A1
(fr)
|
2019-12-20 |
2021-06-23 |
Herantis Pharma Oyj |
Peptides macrocycliques
|
EP3838912A1
(fr)
|
2019-12-20 |
2021-06-23 |
Herantis Pharma Oyj |
Peptides rétro inverses
|
BR112022011749A2
(pt)
|
2020-01-06 |
2022-08-30 |
Vaccinex Inc |
Anticorpos anti-ccr8 e seus usos
|
BR112022013784A2
(pt)
|
2020-01-13 |
2022-10-11 |
Durect Corp |
Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
|
WO2021143906A1
(fr)
|
2020-01-17 |
2021-07-22 |
泰伦基国际有限公司 |
Procédé de traitement d'une lésion nerveuse et maladie associée
|
CN115427066A
(zh)
|
2020-02-06 |
2022-12-02 |
泰伦基国际有限公司 |
一种预防和治疗多发性硬化症的方法和药物
|
WO2021160092A1
(fr)
|
2020-02-11 |
2021-08-19 |
泰伦基国际有限公司 |
Procédé et médicament pour le traitement de la pneumonie virale
|
CA3169325A1
(fr)
|
2020-02-26 |
2021-09-02 |
Jinan Li |
Procede et medicament pour la prevention et le traitement d'un probleme de pression arterielle anormale
|
WO2021173889A1
(fr)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Utilisations de bioconjugués folate-anticorps anti-cd3
|
JP2023517595A
(ja)
|
2020-03-11 |
2023-04-26 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド結合物およびその使用方法
|
CN115427454A
(zh)
|
2020-03-19 |
2022-12-02 |
安进公司 |
针对粘蛋白17的抗体及其用途
|
WO2021190563A1
(fr)
|
2020-03-24 |
2021-09-30 |
泰伦基国际有限公司 |
Procédé et médicament pour le traitement de la maladie de huntington
|
CN115697386A
(zh)
|
2020-03-24 |
2023-02-03 |
泰伦基国际有限公司 |
一种治疗帕金森病的方法和药物
|
TW202144001A
(zh)
|
2020-03-24 |
2021-12-01 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種治療阿茲海默症的方法和藥物
|
TW202143999A
(zh)
|
2020-03-24 |
2021-12-01 |
大陸商深圳瑞健生命科學研究院有限公司 |
一種促進錯誤摺疊蛋白及其聚集物降解的方法和藥物
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
KR20230005298A
(ko)
|
2020-05-11 |
2023-01-09 |
탈렌젠 인터내셔널 리미티드 |
척수성 근위축증의 치료 방법 및 약물
|
US20230235036A1
(en)
|
2020-06-05 |
2023-07-27 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
US20230235056A1
(en)
|
2020-06-19 |
2023-07-27 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor
|
CA3165342A1
(fr)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Traitement du syndrome de sjogren a l'aide de proteines de fusion de type nucleases
|
WO2022023292A2
(fr)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Anticorps ciblant la protéine de spicule de coronavirus et leur utilisation
|
KR20230048059A
(ko)
|
2020-07-31 |
2023-04-10 |
추가이 세이야쿠 가부시키가이샤 |
키메라 수용체를 발현하는 세포를 포함하는 의약 조성물
|
KR20230073200A
(ko)
|
2020-08-20 |
2023-05-25 |
암브룩스, 인코포레이티드 |
항체-tlr 작용제 접합체, 그 방법 및 용도
|
KR20230058081A
(ko)
|
2020-08-26 |
2023-05-02 |
스캔셀 리미티드 |
인간 IgG1의 변형된 FC 영역과 적어도 하나의 이종 항원을 포함하는 폴리펩티드를 암호화하는 핵산
|
WO2022081436A1
(fr)
|
2020-10-15 |
2022-04-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps spécifique du domaine de liaison du récepteur du sars-cov-2 et procédés thérapeutiques
|
WO2022087274A1
(fr)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anticorps qui neutralisent l'activité de l'interféron de type i (ifn)
|
CA3200317A1
(fr)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Molecules bispecifiques multicibles de liaison a un antigene a selectivite accrue
|
EP4248954A1
(fr)
|
2020-11-17 |
2023-09-27 |
Talengen International Limited |
Procédé et médicament pour augmenter le taux de bdnf
|
WO2022105789A1
(fr)
|
2020-11-17 |
2022-05-27 |
泰伦基国际有限公司 |
Procédé et médicament pour augmenter le taux de ngf
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
KR20230156368A
(ko)
|
2021-03-12 |
2023-11-14 |
추가이 세이야쿠 가부시키가이샤 |
중증 근무력증의 치료 또는 예방용의 의약 조성물
|
JP2024512775A
(ja)
|
2021-04-03 |
2024-03-19 |
アンブルックス,インコーポレイテッド |
抗her2抗体薬物コンジュゲート及びその使用
|
EP4329887A1
(fr)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Anticorps bovins chimères humanisés et procédés d'utilisation
|
CA3217180A1
(fr)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Molecules de liaison a l'antigene ciblant cd20 et cd22 destinees a etre utilisees dans des maladies proliferatives
|
IL308198A
(en)
|
2021-05-07 |
2024-01-01 |
Surface Oncology Llc |
Anti-IL-27 antibodies and uses thereof
|
CN117677394A
(zh)
|
2021-05-14 |
2024-03-08 |
克拉里斯生物医疗股份有限公司 |
用于治疗眼部疾病的生长因子的组合物
|
AU2022336625A1
(en)
|
2021-09-03 |
2024-04-11 |
University Of Bern |
Compositions and methods for treating long qt syndrome
|
JPWO2023053282A1
(fr)
|
2021-09-29 |
2023-04-06 |
|
|
AR127568A1
(es)
|
2021-11-03 |
2024-02-07 |
Affimed Gmbh |
Ligandos biespecíficos de cd16a
|
WO2023079493A1
(fr)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Liants de cd16a bispécifiques
|
US20230364031A1
(en)
|
2022-04-19 |
2023-11-16 |
Garth Cooper |
Treatment of brain copper disorders
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
US20230372336A1
(en)
|
2022-05-18 |
2023-11-23 |
Intra-Cellular Therapies, Inc. |
Novel methods
|
US20240026001A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240141050A1
(en)
|
2022-09-02 |
2024-05-02 |
Galderma Holding S.A. |
Treatments for prurigo nodularis
|
WO2024050526A1
(fr)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions et méthodes de traitement du syndrome du qt long
|
WO2024059675A2
(fr)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Composition de stabilisation de molécule bispécifique
|
WO2024076995A1
(fr)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions pour la prévention non chirurgicale de l'odeur et du comportement agressif
|
CN115804830A
(zh)
*
|
2022-12-16 |
2023-03-17 |
浙江圣兆药物科技股份有限公司 |
一种缩短迟滞期的戈舍瑞林缓释植入剂
|